<html lang="en" class="pb-page js" data-request-id="94d66fe6e5cfa538-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d66fe6e5cfa538-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/oTSLY4HSPVFGI1fZDKMZHWn-Drf-rU8BsQqKyGI9Yp7tLP1qk0Z4cvbFh7kUvEFYomqTKp_YEg9MdRn5Fd-WUw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d66fe6e5cfa538-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.23977516423194045"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Nephrology|Pulmonary/Critical Care|Gastroenterology|Clinical Medicine">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Gastroenterology General|Clinical Medicine General|Pulmonary/Critical Care General|Nephrology General|Liver Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2008290","title":"Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome","category":"Research","type":"Original Article","topics":"Gastroenterology General|Clinical Medicine General|Pulmonary/Critical Care General|Nephrology General|Liver Disease","specialties":"Nephrology|Pulmonary/Critical Care|Gastroenterology|Clinical Medicine","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-03-04T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Nephrology|Pulmonary/Critical Care|Gastroenterology|Clinical Medicine\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Gastroenterology General|Clinical Medicine General|Pulmonary/Critical Care General|Nephrology General|Liver Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2008290","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d66fe6e5cfa538-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome"><meta name="dc.Creator" content="Florence Wong"><meta name="dc.Creator" content="S. Chris Pappas"><meta name="dc.Creator" content="Michael P. Curry"><meta name="dc.Creator" content="K. Rajender Reddy"><meta name="dc.Creator" content="Raymond A. Rubin"><meta name="dc.Creator" content="Michael K. Porayko"><meta name="dc.Creator" content="Stevan A. Gonzalez"><meta name="dc.Creator" content="Khalid Mumtaz"><meta name="dc.Creator" content="Nicholas Lim"><meta name="dc.Creator" content="Douglas A. Simonetto"><meta name="dc.Creator" content="Pratima Sharma"><meta name="dc.Creator" content="Arun J. Sanyal"><meta name="dc.Creator" content="Marlyn J. Mayo"><meta name="dc.Creator" content="R. Todd Frederick"><meta name="dc.Creator" content="Shannon Escalante"><meta name="dc.Creator" content="Khurram Jamil"><meta name="dc.Description" content="The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe.We conducted a phase 3 trial to..."><meta name="Description" content="The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe.We conducted a phase 3 trial to..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-03-04"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2008290"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202103043840907"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2022166"><meta name="dc.Relation" content="10.1056/NEJMe2034425"><meta name="dc.Relation" content="YXQYoa2008290"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2008290">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2008290">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2008290">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome | NEJM">
        <meta property="og:title" content="Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2008290">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/e61d9109-6b56-4195-aaaf-975a9aa48752/nejmoa2008290_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/e61d9109-6b56-4195-aaaf-975a9aa48752/nejmoa2008290_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in
many parts of the world and is part of the clinical practice guidelines in Europe.
We conducted a phase 3 trial t...">
        <meta name="twitter:description" content="The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in
many parts of the world and is part of the clinical practice guidelines in Europe.
We conducted a phase 3 trial t...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3405">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2008290">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2008290">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;issue:issue:doi\:10.1056/nejm_2021.384.issue-9;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;article:article:doi\:10.1056/NEJMoa2008290;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2008290" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2008290" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2008290" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2008290" class="inputDoi"><input type="hidden" value="F. Wong and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:818-828" class="inputCitation"><input type="hidden" value="03-03-2021" class="inputEPubDate"><input type="hidden" value="March 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d66fe6e5cfa538-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Florence</span> <span property="familyName">Wong</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">S. Chris</span> <span property="familyName">Pappas</span>, <span property="honorificSuffix">M.D., J.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael P.</span> <span property="familyName">Curry</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">K. Rajender</span> <span property="familyName">Reddy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Raymond A.</span> <span property="familyName">Rubin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael K.</span> <span property="familyName">Porayko</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stevan A.</span> <span property="familyName">Gonzalez</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+9</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Khalid</span> <span property="familyName">Mumtaz</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nicholas</span> <span property="familyName">Lim</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Douglas A.</span> <span property="familyName">Simonetto</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pratima</span> <span property="familyName">Sharma</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Arun J.</span> <span property="familyName">Sanyal</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marlyn J.</span> <span property="familyName">Mayo</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">R. Todd</span> <span property="familyName">Frederick</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shannon</span> <span property="familyName">Escalante</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Khurram</span> <span property="familyName">Jamil</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the CONFIRM Study Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-9</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 3, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">818</span>-<span property="pageEnd">828</span></div><div class="doi">DOI: 10.1056/NEJMoa2008290</div><div class="core-enumeration"><a href="/toc/nejm/384/9"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">9</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DFlorence%2BWong%252C%2BS.%2BChris%2BPappas%252C%2BMichael%2BP.%2BCurry%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D9%26contentID%3D10.1056%252FNEJMoa2008290%26title%3DTerlipressin%2Bplus%2BAlbumin%2Bfor%2Bthe%2BTreatment%2Bof%2BType%2B1%2BHepatorenal%2BSyndrome%26publicationDate%3D03%252F04%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2008290" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DFlorence%2BWong%252C%2BS.%2BChris%2BPappas%252C%2BMichael%2BP.%2BCurry%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D9%26contentID%3D10.1056%252FNEJMoa2008290%26title%3DTerlipressin%2Bplus%2BAlbumin%2Bfor%2Bthe%2BTreatment%2Bof%2BType%2B1%2BHepatorenal%2BSyndrome%26publicationDate%3D03%252F04%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/1132633b-80a3-4597-a58a-893f366617a5/nejmoa2008290.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2008290.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2008290" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2008290" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2008290.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a phase 3 trial to confirm the efficacy and safety of terlipressin plus albumin in adults with HRS-1. The patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days; in both groups, concomitant use of albumin was strongly recommended. The primary end point was verified reversal of HRS, defined as two consecutive serum creatinine measurements of 1.5 mg per deciliter or less at least 2 hours apart and survival without renal-replacement therapy for at least 10 days after the completion of treatment. Four prespecified secondary end points were analyzed with the Hochberg procedure to account for multiple comparisons.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 300 patients underwent randomization — 199 were assigned to the terlipressin group and 101 to the placebo group. Verified reversal of HRS was reported in 63 patients (32%) in the terlipressin group and 17 patients (17%) in the placebo group (P=0.006). With respect to the prespecified secondary end points, HRS reversal, defined as any serum creatinine level of 1.5 mg per deciliter or less during the first 14 days, was reported in 78 patients (39%) in the terlipressin group and 18 (18%) in the placebo group (P&lt;0.001); HRS reversal without renal-replacement therapy by day 30, in 68 (34%) and 17 (17%), respectively (P=0.001); HRS reversal among patients with systemic inflammatory response syndrome (84 patients in the terlipressin group and 48 patients in the placebo group), in 31 (37%) and 3 (6%), respectively (P&lt;0.001); and verified reversal of HRS without recurrence by day 30, in 52 (26%) and 17 (17%), respectively (P=0.08). At day 90, liver transplantations had been performed in 46 patients (23%) in the terlipressin group and 29 patients (29%) in the placebo group, and death occurred in 101 (51%) and 45 (45%), respectively. More adverse events, including abdominal pain, nausea, diarrhea, and respiratory failure, occurred with terlipressin than with placebo. Death within 90 days due to respiratory disorders occurred in 22 patients (11%) in the terlipressin group and 2 patients (2%) in the placebo group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this trial involving adults with cirrhosis and HRS-1, terlipressin was more effective than placebo in improving renal function but was associated with serious adverse events, including respiratory failure. (Funded by Mallinckrodt Pharmaceuticals; CONFIRM ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02770716" target="_blank">NCT02770716</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Type 1 hepatorenal syndrome (HRS-1) is a condition of rapidly progressing kidney failure that occurs in patients with decompensated cirrhosis and ascites.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> Untreated HRS-1 is often fatal, with a median duration of survival of weeks to months.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4-1" href-manipulated="true">3,4</a></sup> Pharmacotherapy with vasopressors may reverse the hemodynamic abnormalities associated with advanced cirrhosis and improve renal perfusion and function in patients with HRS-1.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup></div><div role="paragraph">Terlipressin is a synthetic vasopressin analogue with vasoconstrictor activity in the splanchnic and systemic vasculature.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> This activity results in decreased portal blood inflow and reduced portal hypertension, the main cause of the hemodynamic abnormalities associated with advanced cirrhosis. The consequent redistribution of circulatory volume from the splanchnic to the systemic circulation improves systemic hemodynamics and increases renal perfusion pressure.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7" href-manipulated="true">6,7</a></sup> The increased effective arterial volume also decreases compensatory renal and systemic vasoconstrictor activities, further improving renal hemodynamics in these patients.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-2" href-manipulated="true" aria-label="Reference 3">3</a></sup> The efficacy and safety of terlipressin in patients with HRS-1 have been evaluated in previous randomized, multicenter, placebo-controlled trials of varying sizes.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10" id="body-ref-r10-1" href-manipulated="true">8-10</a></sup> Terlipressin is used for HRS-1 in many parts of the world<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup> and is part of the Clinical Practice Guidelines in Europe.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> The main objective of the CONFIRM Study was to confirm the efficacy and safety of terlipressin plus albumin, as compared with placebo plus albumin, in adults with cirrhosis and HRS-1.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design</h3><div role="paragraph">The <a href="#ap1">protocol</a> (available with the full text of this article at NEJM.org) for this randomized, double-blind, placebo-controlled trial was developed under a special protocol assessment agreement with the Food and Drug Administration as a phase 3 registration trial<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-1" href-manipulated="true" aria-label="Reference 13">13</a></sup> and was approved by the research ethics board at each participating institution.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> The trial was designed by the sponsor, together with the second author. All the trial investigators gathered and vouch for the data. The first author wrote the first and subsequent drafts of the manuscript. A statistician (one of the authors) employed by the sponsor analyzed the data and vouches for the analysis. All the authors had access to the data and vouch for the fidelity of the trial to the protocol.</div><div role="paragraph">The patients underwent an in-hospital screening period of a minimum of 48 hours to establish the diagnosis of HRS-1 (Fig. S1 in the <a href="#ap1">Supplementary Appendix</a>, available at NEJM.org), after which eligibility was confirmed and baseline assessments were made. The serum creatinine level was measured within 8 hours before the first dose of terlipressin or placebo; thereafter, terlipressin or placebo was administered every 6 hours, and this regimen was continued either until 24 hours after a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or less was obtained in two consecutive measurements or until day 14. If on day 4 (after a minimum of 10 doses), the serum creatinine level was at or above the baseline level, the assigned regimen was discontinued. The assigned regimen was also discontinued if a patient received renal-replacement therapy or therapy with another vasopressor or underwent liver transplantation or transjugular intrahepatic portosystemic shunt placement. After completion of the terlipressin or placebo regimen, patients were assessed between days 20 and 40, between days 46 and 74, and between days 76 and 104. Among the patients who were discharged before completing their assigned regimen or who withdrew consent, no further information was collected except on mortality. The patients who were discharged after meeting the criteria for clinical success were monitored for HRS recurrence.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Eligible patients had HRS-1, cirrhosis, ascites, and rapidly progressive kidney failure, with a doubling of the serum creatinine level to at least 2.25 mg per deciliter (199 μmol per liter) within 14 days before randomization. In patients who had an increasing serum creatinine level during the prescreening period, a nomogram was used to determine whether the slope of the patient’s serum creatinine levels was consistent with a trajectory likely to be representative of at least a doubling within 2 weeks.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-2" href-manipulated="true" aria-label="Reference 13">13</a></sup> Patients were excluded if they had a sustained reduction in the serum creatinine level of more than 20% or a decrease to below 2.25 mg per deciliter at least 48 hours after diuretic withdrawal and albumin infusions. Patients in whom treatment with midodrine and octreotide was discontinued before randomization were eligible for enrollment.</div><div role="paragraph">Major exclusion criteria were a serum creatinine level of greater than 7.0 mg per deciliter (619 μmol per liter), one or more large-volume paracenteses of 4 liters or more within 2 days before randomization, the presence of sepsis or uncontrolled bacterial infection (or both) for which antibiotic treatment had been administered for less than 2 days, or severe cardiovascular disease or recent (within 4 weeks before randomization) renal-replacement therapy. Additional details are provided in the <a href="#ap2">Supplementary Appendix</a>. Written informed consent was obtained from all the patients or their legally authorized representatives.</div></section><section id="sec-1-3"><h3>Randomization and Clinical Regimen</h3><div role="paragraph">Patients were randomly assigned in a 2:1 ratio to receive terlipressin plus albumin or placebo plus albumin; randomization was performed with the use of independently generated codes. Stratification factors were a qualifying serum creatinine level (&lt;3.4 mg per deciliter [301 μmol per liter] or ≥3.4 mg per deciliter) and preenrollment large-volume paracentesis (at least one event of ≤4 liters within 3 to 14 days before randomization).</div><div role="paragraph">Patients received terlipressin or placebo in a blinded manner; 1 mg of terlipressin or placebo was administered intravenously over 2 minutes every 5.5 to 6.5 hours. It was strongly recommended that all patients receive albumin (1 g per kilogram of body weight to a maximum of 100 g on day 1 and 20 to 40 g per day thereafter).<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r15" id="body-ref-r15-1" href-manipulated="true">1,15</a></sup> On day 4, patients with a serum creatinine level that had decreased by less than 30% from the baseline level after a minimum of 10 doses of terlipressin or placebo could receive 2 mg every 6 hours, except in those with coronary artery disease, circulatory overload, pulmonary edema, or bronchospasm. If the regimen was interrupted because of adverse events, resumption of the dosing schedule was permitted except in patients who had cardiac or mesenteric ischemia, in whom the regimen was permanently discontinued.</div></section><section id="sec-1-4"><h3>Efficacy End Points</h3><div role="paragraph">The primary efficacy end point was verified reversal of HRS, defined as two consecutive serum creatinine measurements of 1.5 mg per deciliter or less at least 2 hours apart up to day 14 and survival without renal-replacement therapy for at least an additional 10 days. Clinical failure was classified in patients if they received renal-replacement therapy, underwent transjugular intrahepatic portosystemic shunt placement, or received open-label vasopressor therapy before day 14; if the serum creatinine level had not improved by day 4; or if the serum creatinine level had not decreased to 1.5 mg per deciliter or less by day 14. The assigned regimen was discontinued if a patient had clinical failure or underwent liver transplantation. Liver transplantation and death were considered to be competing events when they occurred before a patient could be evaluated for clinical success or failure (nine patients in the terlipressin group and two patients in the placebo group underwent liver transplantation before they could be evaluated, and two patients in the terlipressin group died before they could be evaluated). Patients were considered to be unclassifiable with respect to the primary end point if they had not had a competing event and did not meet the criteria for clinical success or failure or if data on the serum creatinine level were not available because of hospital discharge, withdrawal of consent, or another reason during the planned treatment period (up to 14 days) and the day after; the results for these patients were imputed with the use of multiple imputation (additional details are provided below and in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">Four prespecified secondary efficacy end points were adjusted for multiple comparisons: HRS reversal, defined as a serum creatinine level of 1.5 mg per deciliter or less; durability of HRS reversal, defined as HRS reversal without renal-replacement therapy to day 30; HRS reversal among patients with systemic inflammatory response syndrome; and verified reversal of HRS without recurrence of HRS by day 30. The same imputation method used in the analysis of the primary end point was applied to the secondary end points. Additional details of the end-point definitions are provided in Table S1.</div></section><section id="sec-1-5"><h3>Safety</h3><div role="paragraph">Data on nonserious adverse events were collected up to 7 days after the end of the treatment period, and data on serious adverse events were collected up to 30 days after the end of the treatment period. Mortality was documented for up to 90 days after the first dose of terlipressin or placebo.</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">Efficacy analyses were performed in the intention-to-treat population, which comprised all patients who underwent randomization. The sample size for the analysis of the primary efficacy end point was calculated on the basis of pooled estimates of HRS reversal (8.4% with terlipressin and 12.5% with placebo) from two previous trials of terlipressin for HRS-1.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r10" id="body-ref-r10-2" href-manipulated="true">8,10</a></sup> With a randomization ratio of 2:1 between terlipressin and placebo and an interim analysis after 50% of the patients completed the planned treatment period of up to 14 days or were discharged, a sample size of 300 patients was expected to provide 90% power to detect a significant difference between the groups with respect to the primary efficacy end point.</div><div role="paragraph">In the prespecified analysis, clinical success with respect to the primary end point required improvement in the serum creatinine level while receiving terlipressin or placebo, and clinical failure was classified in all patients who discontinued their assigned regimen before meeting the criteria for clinical success. In accordance with the intention-to-treat principle, we modified the definition of clinical success so that it was not required to continue receiving terlipressin or placebo in order to achieve clinical success. For the patients who withdrew from the trial or were discharged and did not have available data on the serum creatinine level through day 15, we used multiple imputation to account for missing end-point data. Multiple imputation was performed with the use of an imputation model that included seven variables (additional details are provided in the <a href="#ap2">Supplementary Appendix</a>). In the analysis of the primary and secondary end points, the PROC MI, PROC SURVEYFREQ, PROC GENMOD, and PROC MIANALYZE procedures in SAS software, version 4 (SAS Institute), were used to generate and combine the results on the basis of imputations.</div><div role="paragraph">A Hochberg procedure was used to adjust for multiple testing of the four secondary end points. A detailed statistical analysis plan is provided in the <a href="#ap1">protocol</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">The trial was conducted between July 13, 2016, and July 24, 2019, at 60 sites in the United States and Canada. A total of 300 patients were randomly assigned to receive terlipressin (199 patients) or placebo (101 patients). The clinical and demographic characteristics of the patients at baseline were generally well balanced between the trial groups (<a href="#t1">Table 1</a> and Table S2). Concomitant albumin was administered in 165 patients (83%) in the terlipressin group (mean [±SD] total dose per person, 199.4±146.8 g over a median of 5.0 days) and 92 patients (91%) in the placebo group (mean total dose, 239.5±183.6 g over a median of 5.5 days). A total of 121 patients (61%) in the terlipressin group and 61 patients (60%) in the placebo group had previously received midodrine and octreotide. Details regarding the screening, randomization, and follow-up of the patients are provided in <a href="#f1">Figure 1</a> and Figure S2.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2008290_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2008290_f1.jpg"><img src="/cms/10.1056/NEJMoa2008290/asset/e61d9109-6b56-4195-aaaf-975a9aa48752/assets/images/large/nejmoa2008290_f1.jpg" height="3405" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">The categories of “withdrew consent” and “had other reason for end of follow-up” are not cumulative; the categories of “lost to follow-up” and “died” are cumulative. Some patients had more than one reason for ending follow-up. Among the reasons for the end of the treatment period of up to 14 days, the category of “died” in the terlipressin group applies to 4 patients who died during the time they were receiving the drug. A total of 9 patients in the terlipressin group and 1 patient in the placebo group died during the on-treatment period (defined as the period from the first dose up to 24 hours after discontinuation of the regimen). The patients who died within 24 hours after discontinuation of the regimen were included in the category “had other reason.” HRS denotes hepatorenal syndrome, and TIPS transjugular intrahepatic portosystemic shunt.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t1.jpg"><img src="/cms/10.1056/NEJMoa2008290/asset/83108354-012a-45da-92cb-1b22d4e66dd3/assets/images/large/nejmoa2008290_t1.jpg" height="2157" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Terlipressin<br>(N=199)</th><th class="txxr-borders">Placebo<br>(N=101)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">54.0±11.3</td><td class="xxxr-borders shading">53.6±11.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">120 (60)</td><td class="xxxr-borders">59 (58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Cause of liver cirrhosis — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Alcohol use</td><td class="xxxx-borders">134 (67)</td><td class="xxxr-borders">67 (66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonalcoholic steatohepatitis</td><td class="xxxx-borders shading">42 (21)</td><td class="xxxr-borders shading">24 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Viral hepatitis</td><td class="xxxx-borders">35 (18)</td><td class="xxxr-borders">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Autoimmune hepatitis</td><td class="xxxx-borders shading">10 (5)</td><td class="xxxr-borders shading">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Primary biliary cirrhosis</td><td class="xxxx-borders">5 (3)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other cause or cryptogenic liver disease</td><td class="xxxx-borders shading">15 (8)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Alcoholic hepatitis — no. (%)</td><td class="xxxx-borders">81 (41)</td><td class="xxxr-borders">39 (39)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Systemic inflammatory response syndrome — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">84 (42)</td><td class="xxxr-borders shading">48 (48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Mean arterial pressure — mm Hg</td><td class="xxxx-borders">78.7±12.1</td><td class="xxxr-borders">77.5±9.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serum sodium level — mmol/liter</td><td class="xxxx-borders shading">133.1±5.6</td><td class="xxxr-borders shading">133.3±5.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serum creatinine level — mg/dl</td><td class="xxxx-borders">3.5±1.0</td><td class="xxxr-borders">3.5±1.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Total bilirubin level — mg/dl</td><td class="xxxx-borders shading">13.1±13.5</td><td class="xxxr-borders shading">15.0±15.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Albumin level — g/dl</td><td class="xxxx-borders">3.7±0.7</td><td class="xxxr-borders">4.0±2.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Child–Pugh score<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">10.0±1.85</td><td class="xxxr-borders shading">10.2±1.89</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">MELD score<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xbxx-borders">32.7±6.6</td><td class="xbxr-borders">33.1±6.2</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. To convert the values for bilirubin to micromoles per liter, multiply by 17.1. To convert the values for serum creatinine to micromoles per liter, multiply by 88.4.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Systemic inflammatory response syndrome is diagnosed when two or more of the following criteria are met: body temperature lower than 36°C or higher than 38°C; heart rate greater than 90 beats per minute; respiratory rate greater than 20 breaths per minute or partial pressure of arterial carbon dioxide lower than 4.3 kPa (32 mm Hg); white-cell count lower than 4000 cells per cubic millimeter or higher than 12,000 cells per cubic millimeter; or the presence of more than 10% immature neutrophils (band forms).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The Child–Pugh score is based on five clinical measures of liver function (total bilirubin level, serum albumin level, prothrombin time, ascites, and hepatic encephalopathy, with each measure graded according to severity); scores range from 5 to 15, with higher scores indicating more advanced liver disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The Model of End-Stage Liver Disease (MELD) score is based on the international normalized ratio for prothrombin time (INR) and serum bilirubin and creatinine levels and is calculated as follows: [3.78×ln(serum bilirubin in milligrams per deciliter)]+[11.2×ln(INR)]+[9.57×ln(serum creatinine in milligrams per deciliter)]+6.43, where ln is natural log. Scores range from 6 to 40, with higher scores indicating more severe disease, and have been shown to be predictive of survival in a wide variety of patients with cirrhosis.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy End Points</h3><div role="paragraph">The percentage of patients who had verified reversal of HRS (the primary end point) was significantly higher in the terlipressin group than in the placebo group (32% [63 patients] vs. 17% [17 patients]; P=0.006) (<a href="#t2">Table 2</a>); 17 patients in the terlipressin group and 9 patients in the placebo group were considered to be unclassifiable with respect to the primary end point (<a href="#f1">Figure 1</a> and Fig. S2). The reasons for failure to have verified reversal of HRS are detailed in Table S3. Three of the four secondary end points that were included in the Hochberg procedure to adjust for multiple testing were statistically significant (<a href="#t2">Table 2</a>); the reasons for failure with respect to the secondary end points are detailed in Table S4. The results with respect to the additional secondary end points and other clinical events are reported in <a href="#t3">Table 3</a> and Table S5. Figure S3 shows the cumulative numbers of patients who had verified reversal of HRS and HRS reversal, respectively. The results of the prespecified analysis without multiple imputation are reported in Figure S4. Among 58 patients in the terlipressin group who had verified reversal of HRS and completed 30 days of follow-up, 10 (17%) had recurrence of HRS.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t2.jpg"><img src="/cms/10.1056/NEJMoa2008290/asset/1b188629-4b46-4e38-929b-2bf7616a1892/assets/images/large/nejmoa2008290_t2.jpg" height="2795" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Terlipressin</th><th class="txxx-borders">Placebo</th><th class="txxr-borders">P Value</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>number/total number of patients (percent)</span></th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Primary end point of verified reversal of HRS</b><a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">0.006</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Clinical success</td><td class="xxxx-borders">63/199 (32)</td><td class="xxxx-borders">17/101 (17)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Clinical failure</td><td class="xxxx-borders shading">121/199 (61)</td><td class="xxxx-borders shading">81/101 (80)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Competing event<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders shading">10/199 (5)</td><td class="xxxx-borders shading">2/101 (2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death</td><td class="xxxx-borders">5/199 (3)</td><td class="xxxx-borders">0/101</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Secondary end points included in multiplicity adjustment</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HRS reversal<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">78/199 (39)</td><td class="xxxx-borders shading">18/101 (18)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">105/199 (53)</td><td class="xxxx-borders">79/101 (78)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">11/199 (6)</td><td class="xxxx-borders">4/101 (4)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">5/199 (3)</td><td class="xxxx-borders shading">0/101</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HRS reversal with no renal-replacement therapy through 30 days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">68/199 (34)</td><td class="xxxx-borders shading">17/101 (17)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">116/199 (58)</td><td class="xxxx-borders">80/101 (79)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">10/199 (5)</td><td class="xxxx-borders">3/101 (3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">5/199 (3)</td><td class="xxxx-borders shading">0/101</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HRS reversal in patients with systemic inflammatory response syndrome</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">31/84 (37)</td><td class="xxxx-borders shading">3/48 (6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">45/84 (54)</td><td class="xxxx-borders">43/48 (90)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">4/84 (5)</td><td class="xxxx-borders">1/48 (2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">5/84 (6)</td><td class="xxxx-borders shading">0/48</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Verified reversal of HRS with no recurrence through 30 days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.08</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">52/199 (26)</td><td class="xxxx-borders shading">17/101 (17)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">131/199 (66)</td><td class="xxxx-borders">81/101 (80)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">10/199 (5)</td><td class="xxxx-borders">2/101 (2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xbxx-borders shading">5/199 (3)</td><td class="xbxx-borders shading">0/101</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Four Secondary End Points Included in Multiplicity Adjustment.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Efficacy analyses were performed in the intention-to-treat population, which included all patients who underwent randomization. Because of multiple imputation, the total number of patients in a trial group who had clinical success, clinical failure, or a competing event with respect to each end point is either 1 less or 1 greater than the total number of patients listed in that trial group. The numbers imputed for the primary end point of verified hepatorenal syndrome (HRS) reversal were 17 in the terlipressin group and 9 in the placebo group; for HRS reversal, 16 and 8, respectively; for HRS reversal with no renal-replacement therapy through 30 days, 6 and 6, respectively; for HRS reversal in patients with systemic inflammatory response syndrome, 8 and 3, respectively; and for verified reversal of HRS with no recurrence through 30 days, 17 and 9, respectively.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Verified reversal of HRS was defined as two consecutive serum creatinine measurements of 1.5 mg per deciliter (133 μmol per liter) or less at least 2 hours apart and survival without renal-replacement therapy for at least 10 days.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Competing events included deaths or liver transplantations that occurred before the patient met the criteria for clinical success or failure. The reported numbers of competing events involving deaths and liver transplantations include outcomes that were assigned on the basis of multiple imputation.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">HRS reversal was defined as any serum creatinine level of 1.5 mg per deciliter or less while receiving terlipressin or placebo.</div></div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t3.jpg"><img src="/cms/10.1056/NEJMoa2008290/asset/074cf611-4811-4726-a5d1-118018bee30b/assets/images/large/nejmoa2008290_t3.jpg" height="1389" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Terlipressin<br>(N=199)</th><th class="txxr-borders">Placebo<br>(N=101)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Received renal-replacement therapy</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 14</td><td class="xxxx-borders">45 (23)</td><td class="xxxr-borders">35 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 30</td><td class="xxxx-borders shading">51 (26)</td><td class="xxxr-borders shading">36 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 60</td><td class="xxxx-borders">56 (28)</td><td class="xxxr-borders">38 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 90</td><td class="xxxx-borders shading">58 (29)</td><td class="xxxr-borders shading">39 (39)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Underwent liver transplantation</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 14</td><td class="xxxx-borders shading">19 (10)</td><td class="xxxr-borders shading">15 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 30</td><td class="xxxx-borders">32 (16)</td><td class="xxxr-borders">22 (22)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 60</td><td class="xxxx-borders shading">43 (22)</td><td class="xxxr-borders shading">28 (28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 90</td><td class="xxxx-borders">46 (23)</td><td class="xxxr-borders">29 (29)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Died</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 14</td><td class="xxxx-borders">53 (27)</td><td class="xxxr-borders">24 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 30</td><td class="xxxx-borders shading">78 (39)</td><td class="xxxr-borders shading">36 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 60</td><td class="xxxx-borders">91 (46)</td><td class="xxxr-borders">41 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Day 90</td><td class="xbxx-borders shading">101 (51)</td><td class="xbxr-borders shading">45 (45)</td></tr></tbody></table></div><figcaption><div class="caption">Additional Secondary End Points Assessed at Days 14, 30, 60, and 90.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The number of deaths or liver transplantations up to day 30 includes those classified as competing events and those that occurred after a patient met the criteria for clinical success or failure.</div></div></div></figcaption></figure></div><div role="paragraph">Over a mean duration of follow-up of 55.3 days, 46 patients (23%) in the terlipressin group received a liver transplant. In the placebo group, 29 patients (29%) received a liver transplant over a mean duration of follow-up of 56.1 days (Fig. S5 and Table S6). Overall or transplantation-free survival up to 90 days did not differ significantly between the two groups (Fig. S6). Other results, including Model of End-Stage Liver Disease (MELD) score, serum albumin level, and mean arterial pressure, during the treatment period are reported in Figures S7 to S9. The results of post hoc exploratory analyses of baseline variables associated with HRS reversal are reported in Figures S10 to S12. Other clinical information is provided in Table S7, and the results of other efficacy end points are reported in Table S8.</div><div role="paragraph">By day 90, death occurred in 101 patients (51%) in the terlipressin group and in 45 patients (45%) in the placebo group (difference, 6 percentage points; 95% confidence interval [CI], −6 to 18).</div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph">The safety population included all the patients who underwent randomization and received at least one dose of terlipressin or placebo. One patient in the placebo group did not receive a first dose, and 1 patient who had been assigned to receive placebo inadvertently received one dose of terlipressin and was therefore assigned to the terlipressin group in the safety population.</div><div role="paragraph">Adverse events of any severity, including serious adverse events, were reported in 176 of 200 patients (88%) in the terlipressin group and 88 of 99 patients (89%) in the placebo group (<a href="#t4">Table 4</a>). The most frequently reported adverse events in the overall safety population (299 patients) were abdominal pain (45 patients [15%]), nausea (42 patients [14%]), diarrhea (33 patients [11%]), hepatic encephalopathy (33 patients [11%]), and dyspnea (30 patients [10%]) (Table S9). The percentage of patients who had abdominal pain, nausea, diarrhea, or respiratory failure was higher in the terlipressin group than in the placebo group (14% [28 patients] vs. 5% [5 patients]). The percentage of patients who had dose interruptions related to adverse events was similar in the two groups (7% in each group), whereas the percentage of patients who had permanent discontinuations of the assigned regimen owing to adverse events was higher in the terlipressin group than in the placebo group (12% [24 patients] vs. 5% [5 patients]) (Table S10a). A total of 9 patients (4%) in the terlipressin group and 1 patient (1%) in the placebo group died during the on-treatment period (defined as the period from the initial dose to 24 hours after discontinuation of the regimen). Four patients in the terlipressin group died during the time they were receiving the drug; 5 other patients in the terlipressin group and 1 patient in the placebo group died within 24 hours after discontinuation of the regimen. The most common cause of death while receiving terlipressin or placebo was respiratory failure (6 patients [3%] in the terlipressin group and 0 patients in the placebo group), whereas the most common causes of death up to 90 days were hepatobiliary disorders (45 patients [22%] in the terlipressin group vs. 27 patients [27%] in the placebo group), respiratory disorders (22 [11%] vs. 2 [2%]), and infections (14 [7%] vs. 3 [3%]). All adverse events leading to death by day 14 are reported in Table S11, and adverse events leading to death up to 90 days are reported in Table S10b.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 4</div><nav><a href="#t4" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t4.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t4" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t4.jpg"><img src="/cms/10.1056/NEJMoa2008290/asset/ff44b46b-90d6-4edb-b39a-aa89db43bd1b/assets/images/large/nejmoa2008290_t4.jpg" height="2527" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Terlipressin<br>(N=200)</th><th class="txxr-borders">Placebo<br>(N=99)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse events of any grade<a href="#t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">176 (88)</td><td class="xxxr-borders shading">88 (89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Adverse events leading to discontinuation of the trial regimen</td><td class="xxxx-borders">24 (12)</td><td class="xxxr-borders">5 (5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Serious adverse events with an incidence of ≥3% in either trial group<a href="#t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Any</td><td class="xxxx-borders">130 (65)</td><td class="xxxr-borders">60 (61)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Cardiac disorders</td><td class="xxxx-borders shading">8 (4)</td><td class="xxxr-borders shading">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Atrial fibrillation</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Gastrointestinal disorders</td><td class="xxxx-borders shading">30 (15)</td><td class="xxxr-borders shading">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">10 (5)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Gastrointestinal hemorrhage</td><td class="xxxx-borders shading">8 (4)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">General disorders and administration-site conditions</td><td class="xxxx-borders">11 (6)</td><td class="xxxr-borders">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Multiple organ dysfunction syndrome</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hepatobiliary disorders</td><td class="xxxx-borders">37 (18)</td><td class="xxxr-borders">29 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Chronic hepatic failure</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Alcoholic cirrhosis</td><td class="xxxx-borders">4 (2)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Hepatic cirrhosis</td><td class="xxxx-borders shading">6 (3)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hepatic failure</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">10 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Worsening of HRS</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Infections and infestations</td><td class="xxxx-borders">19 (10)</td><td class="xxxr-borders">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">4 (2)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Sepsis</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nervous system disorders</td><td class="xxxx-borders shading">13 (6)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hepatic encephalopathy</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Respiratory, thoracic, and mediastinal disorders<a href="#t4fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">33 (16)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Acute respiratory failure</td><td class="xxxx-borders">8 (4)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Respiratory failure</td><td class="xxxx-borders shading">20 (10)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Vascular disorders</td><td class="xxxx-borders">10 (5)</td><td class="xxxr-borders">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23 shading" data-xml-align="left">Shock</td><td class="xbxx-borders shading">5 (2)</td><td class="xbxr-borders shading">3 (3)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events in the Safety Population.<a href="#t4fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t4fn1" role="paragraph">The safety population included all patients who underwent randomization and received at least one dose of terlipressin or placebo. For each event category, the patients were counted once even if they had multiple events in that category. One patient in the placebo group did not receive a first dose, and one patient who had been assigned to receive placebo inadvertently received one dose of terlipressin and was therefore assigned to the terlipressin group in the safety analysis.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t4fn2" role="paragraph">The numbers of events include those that occurred up to 7 days after the end of the treatment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t4fn3" role="paragraph">The numbers of events include those that occurred up to 30 days after the end of the treatment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t4fn4" role="paragraph">The numbers reported for acute respiratory failure or respiratory failure are for patients with the condition as coded by the investigator; there is no overlap.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this multicenter, double-blind, randomized, controlled trial of terlipressin for the treatment of HRS-1, the percentage of patients who had verified reversal of HRS was significantly higher with terlipressin than with placebo. The primary end point in the CONFIRM Study consisted of three components (two consecutive serum creatinine measurements of ≤1.5 mg per deciliter at least 2 hours apart by day 14, absence of renal-replacement therapy for at least 10 days, and survival for at least 10 days). Combined, these three components provided a clinically meaningful measure of efficacy in improving kidney function and initial survival for 10 days after completion of treatment. The efficacy results were similar to those of trials from Europe<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-2" href-manipulated="true" aria-label="Reference 9">9</a></sup> and North America.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r10" id="body-ref-r10-3" href-manipulated="true">8,10</a></sup> The durability of HRS reversal with terlipressin also persisted to day 30 without the use of renal-replacement therapy; this is a clinically relevant observation because renal-replacement therapy poses many challenges for patients with advanced cirrhosis.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> However, the reversal of HRS with terlipressin did not improve 90-day survival as compared with placebo (101 patients [51%]) vs. 45 patients [45%]; difference, 6 percentage points, 95% CI, −6 to 18). Patients in the terlipressin group were more likely to have respiratory failure and to die from respiratory disorders within 90 days after the first dose (22 patients [11%] vs. 2 patients [2%]), which probably contributed to the numerical difference in mortality. Although terlipressin improves kidney function, patients with advanced liver disease may nonetheless continue to have other complications of decompensated cirrhosis unrelated to HRS-1 and die from these complications.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18" href-manipulated="true">17,18</a></sup> This state of decompensation can be corrected only with liver transplantation. The percentage of patients who received a liver transplant within 90 days after the first dose was lower in the terlipressin group than in the placebo group (23% vs. 29%) despite there being no difference in MELD score between the two groups during the treatment period. MELD scores at the time of transplantation were not collected; therefore, it is not possible to determine whether a terlipressin-related change in MELD score had an effect on transplantation priority. It is possible that respiratory complications and sepsis or septic shock in the terlipressin group could have prevented liver transplantation.</div><div role="paragraph">The efficacy of terlipressin, as compared with placebo, in reversing HRS-1 was more pronounced among the subgroup of patients with systemic inflammatory response syndrome. Inflammatory cytokines have been implicated in the pathogenesis of HRS-1.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20" id="body-ref-r20" href-manipulated="true">19,20</a></sup> It has been postulated that terlipressin, by reducing portal pressure, may lead to a decrease in the extent of bacterial translocation across the gut wall and a consequent reduction in endotoxemia and proinflammatory cytokine production in patients with decompensated cirrhosis, changes that would facilitate the response to the hemodynamic effects of terlipressin.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22" id="body-ref-r22" href-manipulated="true">21,22</a></sup></div><div role="paragraph">Among 58 patients in the terlipressin group who had verified reversal of HRS and completed 30 days of follow-up, 10 (17%) had recurrence of HRS, a percentage similar to that reported in the literature.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> Terlipressin addresses the hemodynamic abnormalities behind HRS-1 but does not eliminate the clinical milieu of advanced cirrhosis from which the syndrome arises.</div><div role="paragraph">Overall, the results of the CONFIRM Study are in accordance with the data from previous clinical trials that provided evidence that terlipressin improves kidney function in patients with HRS-1.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r8 r10 r24 r25 r26 r27" id="body-ref-r27" href-manipulated="true">4,8,10,24–27</a></sup> Liver transplantation, which eliminates end-stage liver disease,<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r28" id="body-ref-r28" href-manipulated="true">15,28</a></sup> remains the only curative treatment for HRS-1. However, the majority of patients with HRS-1 do not have access to a timely liver transplantation, and alternative vasoconstrictor pharmacotherapies either have not been rigorously assessed in large clinical trials or have been shown to be ineffective.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r29 r30" id="body-ref-r30" href-manipulated="true">24,29,30</a></sup></div><div role="paragraph">The incidence of serious adverse events was higher in the terlipressin group than in the placebo group. Abdominal pain, skin discoloration, intestinal ischemia, cardiac ischemia, cyanosis, bradycardia, and diarrhea are well-recognized potential adverse effects of terlipressin. The incidences of respiratory failure and acute respiratory failure were higher in the terlipressin group than in the placebo group, a finding that is possibly related to the known cardiovascular and pulmonary effects of terlipressin.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31 r32 r33 r34" id="body-ref-r34" href-manipulated="true">31-34</a></sup> Terlipressin should be used with caution in patients who have the most advanced liver disease. Death within 90 days due to respiratory disorders occurred in 11% of patients in the terlipressin group, as compared with 2% of patients in the placebo group.</div><div role="paragraph">Our trial has some limitations. The trial was not powered to assess the between-group difference in survival. A detailed follow-up beyond 90 days that included an assessment of prespecified outcomes after liver transplantation was not performed.</div><div role="paragraph">In the CONFIRM trial, the use of terlipressin plus albumin was more efficacious than placebo plus albumin in producing verified reversal of HRS in patients with decompensated cirrhosis and HRS-1. Terlipressin was associated with serious adverse events, including respiratory failure.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Mallinckrodt Pharmaceuticals</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank Michael D. Morren, R.Ph., M.B.A., of Peloton Advantage, an OPEN Health company, for editorial assistance, conducted in accordance with Good Publication Practice and the International Committee of Medical Journal Editors guidelines, with the organization of the <a href="#ap2">Supplementary Appendix</a> (funded by Mallinckrodt Pharmaceuticals).</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2008290_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2008290/suppl_file/nejmoa2008290_protocol.pdf" download="nejmoa2008290_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2008290_protocol.pdf" data-doi="10.1056/NEJMoa2008290">Download</a></li><li>3.20 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2008290_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2008290/suppl_file/nejmoa2008290_appendix.pdf" download="nejmoa2008290_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2008290_appendix.pdf" data-doi="10.1056/NEJMoa2008290">Download</a></li><li>1.54 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2008290_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2008290/suppl_file/nejmoa2008290_disclosures.pdf" download="nejmoa2008290_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2008290_disclosures.pdf" data-doi="10.1056/NEJMoa2008290">Download</a></li><li>734.33 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2008290_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2008290/suppl_file/nejmoa2008290_data-sharing.pdf" download="nejmoa2008290_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2008290_data-sharing.pdf" data-doi="10.1056/NEJMoa2008290">Download</a></li><li>69.73 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <em>Gut</em> 2007;56:1310-1318.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17389705/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248725600025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis%2C+prevention+and+treatment+of+hepatorenal+syndrome+in+cirrhosis.&amp;publication_year=2007&amp;journal=Gut&amp;pages=1310-1318&amp;pmid=17389705" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with decompensated cirrhosis and ascites. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] day 1 and 20 to 40 g per day thereafter). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. <em>Aliment Pharmacol Ther</em> 2017;45:1390-1402.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/apt.14052" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28370090/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400785900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Reversal+of+hepatorenal+syndrome+type+1+with+terlipressin+plus+albumin+vs.+placebo+plus+albumin+in+a+pooled+analysis+of+the+OT-0401+and+REVERSE+randomised+clinical+studies.&amp;publication_year=2017&amp;journal=Aliment+Pharmacol+Ther&amp;pages=1390-1402&amp;doi=10.1111%2Fapt.14052&amp;pmid=28370090" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. <em>Nat Rev Dis Primers</em> 2018;4:23-23.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41572-018-0022-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30213943/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444654600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hepatorenal+syndrome.&amp;publication_year=2018&amp;journal=Nat+Rev+Dis+Primers&amp;pages=23-23&amp;doi=10.1038%2Fs41572-018-0022-7&amp;pmid=30213943" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] duration of survival of weeks to months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] renal hemodynamics in these patients. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Zheng J-N, Han Y-J, Zou T-T, et al. Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. <em>Expert Rev Gastroenterol Hepatol</em> 2017;11:1009-1018.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/17474124.2017.1356223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28708431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414938300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+of+vasoconstrictor+therapies+for+type+1+hepatorenal+syndrome%3A+a+network+meta-analysis.&amp;publication_year=2017&amp;journal=Expert+Rev+Gastroenterol+Hepatol&amp;pages=1009-1018&amp;doi=10.1080%2F17474124.2017.1356223&amp;pmid=28708431" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] duration of survival of weeks to months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and function in patients with HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] kidney function in patients with HRS-1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Jamil K, Pappas SC, Devarakonda KR. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V<sub>1</sub> and V<sub>2</sub>. <em>J Exp Pharmacol</em> 2017;10:1-7.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/JEP.S146034" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29302194/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+vitro+binding+and+receptor-mediated+activity+of+terlipressin+at+vasopressin+receptors+V1+and+V2.&amp;publication_year=2017&amp;journal=J+Exp+Pharmacol&amp;pages=1-7&amp;doi=10.2147%2FJEP.S146034&amp;pmid=29302194" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Møller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. <em>Scand J Gastroenterol</em> 2004;39:486-492.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/00365520310008728" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15180188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000221184700014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+terlipressin+on+blood+volume+distribution+in+patients+with+cirrhosis.&amp;publication_year=2004&amp;journal=Scand+J+Gastroenterol&amp;pages=486-492&amp;doi=10.1080%2F00365520310008728&amp;pmid=15180188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. <em>Crit Care Med</em> 2011;39:1329-1334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0b013e3182120842" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21336108/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290715000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+use+of+terlipressin+during+living+donor+liver+transplantation%3A+effects+on+systemic+and+splanchnic+hemodynamics+and+renal+function.&amp;publication_year=2011&amp;journal=Crit+Care+Med&amp;pages=1329-1334&amp;doi=10.1097%2FCCM.0b013e3182120842&amp;pmid=21336108" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. <em>Gastroenterology</em> 2008;134:1360-1368.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2008.02.014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18471513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255676700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized%2C+prospective%2C+double-blind%2C+placebo-controlled+trial+of+terlipressin+for+type+1+hepatorenal+syndrome.&amp;publication_year=2008&amp;journal=Gastroenterology&amp;pages=1360-1368&amp;doi=10.1053%2Fj.gastro.2008.02.014&amp;pmid=18471513" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] placebo-controlled trials of varying sizes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] previous trials of terlipressin for HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and North America. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] kidney function in patients with HRS-1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Martín-Llahí M, Pépin M-N, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. <em>Gastroenterology</em> 2008;134:1352-1359.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2008.02.024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18471512/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255676700015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+and+albumin+vs+albumin+in+patients+with+cirrhosis+and+hepatorenal+syndrome%3A+a+randomized+study.&amp;publication_year=2008&amp;journal=Gastroenterology&amp;pages=1352-1359&amp;doi=10.1053%2Fj.gastro.2008.02.024&amp;pmid=18471512" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] placebo-controlled trials of varying sizes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were similar to those of trials from Europe </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. <em>Gastroenterology</em> 2016;150(7):1579-1589.e2.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2016.02.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26896734/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376778800030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+plus+albumin+is+more+effective+than+albumin+alone+in+improving+renal+function+in+patients+with+cirrhosis+and+hepatorenal+syndrome+type+1.&amp;publication_year=2016&amp;journal=Gastroenterology&amp;pages=1579-1589.e2&amp;doi=10.1053%2Fj.gastro.2016.02.026&amp;pmid=26896734" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] placebo-controlled trials of varying sizes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] previous trials of terlipressin for HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and North America. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] kidney function in patients with HRS-1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Papaluca T, Gow P. Terlipressin: current and emerging indications in chronic liver disease. <em>J Gastroenterol Hepatol</em> 2018;33:591-598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/jgh.14009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28981166/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425735300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin%3A+current+and+emerging+indications+in+chronic+liver+disease.&amp;publication_year=2018&amp;journal=J+Gastroenterol+Hepatol&amp;pages=591-598&amp;doi=10.1111%2Fjgh.14009&amp;pmid=28981166" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. <em>J Hepatol</em> 2018;69:406-460.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2018.03.024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29653741/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438753600020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EASL+clinical+practice+guidelines+for+the+management+of+patients+with+decompensated+cirrhosis.&amp;publication_year=2018&amp;journal=J+Hepatol&amp;pages=406-460&amp;doi=10.1016%2Fj.jhep.2018.03.024&amp;pmid=29653741" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Special protocol assessment: guidance for industry. April 2018 (<a href="https://www.fda.gov/media/97618/download">https://www.fda.gov/media/97618/download</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Food+and+Drug+Administration.+Special+protocol+assessment%3A+guidance+for+industry.+April+2018+%28https%3A%2F%2Fwww.fda.gov%2Fmedia%2F97618%2Fdownload%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] as a phase 3 registration trial </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of at least a doubling within 2 weeks. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Jamil K, Pappas SC, Wong F, Sanyal AJ. Verified hepatorenal syndrome reversal as a robust multi-component primary end point: the CONFIRM study trial design. <em>J Clin Trials</em> 2019;11:67-73.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Verified+hepatorenal+syndrome+reversal+as+a+robust+multi-component+primary+end+point%3A+the+CONFIRM+study+trial+design.&amp;publication_year=2019&amp;journal=J+Clin+Trials&amp;pages=67-73" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <em>J Hepatol</em> 2015;62:968-974.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2014.12.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25638527/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000351305300029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis+and+management+of+acute+kidney+injury+in+patients+with+cirrhosis%3A+revised+consensus+recommendations+of+the+International+Club+of+Ascites.&amp;publication_year=2015&amp;journal=J+Hepatol&amp;pages=968-974&amp;doi=10.1016%2Fj.jhep.2014.12.029&amp;pmid=25638527" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] day 1 and 20 to 40 g per day thereafter). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which eliminates end-stage liver disease, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Allegretti AS, Vela Parada X, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. <em>Clin J Am Soc Nephrol</em> 2018;13:16-25.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2215/CJN.03610417" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29122911/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419758100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prognosis+of+patients+with+cirrhosis+and+AKI+who+initiate+RRT.&amp;publication_year=2018&amp;journal=Clin+J+Am+Soc+Nephrol&amp;pages=16-25&amp;doi=10.2215%2FCJN.03610417&amp;pmid=29122911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Piano S, Brocca A, Angeli P. Renal function in cirrhosis: a critical review of available tools. <em>Semin Liver Dis</em> 2018;38:230-241.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0038-1661372" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30041275/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439917800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Renal+function+in+cirrhosis%3A+a+critical+review+of+available+tools.&amp;publication_year=2018&amp;journal=Semin+Liver+Dis&amp;pages=230-241&amp;doi=10.1055%2Fs-0038-1661372&amp;pmid=30041275" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Reiberger T. When should we stop treatment with terlipressin and albumin for patients with hepatorenal syndrome? <em>Clin Gastroenterol Hepatol</em> 2018;16:1710-1711.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2018.04.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29684461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000447826300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=When+should+we+stop+treatment+with+terlipressin+and+albumin+for+patients+with+hepatorenal+syndrome%3F&amp;publication_year=2018&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=1710-1711&amp;doi=10.1016%2Fj.cgh.2018.04.020&amp;pmid=29684461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. <em>Kidney Int</em> 2015;87:509-515.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ki.2014.338" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25296092/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350533300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Renal+dysfunction+in+cirrhosis+is+not+just+a+vasomotor+nephropathy.&amp;publication_year=2015&amp;journal=Kidney+Int&amp;pages=509-515&amp;doi=10.1038%2Fki.2014.338&amp;pmid=25296092" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. <em>Shock</em> 2014;41:3-11.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/SHK.0000000000000052" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24346647/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336209200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+unified+theory+of+sepsis-induced+acute+kidney+injury%3A+inflammation%2C+microcirculatory+dysfunction%2C+bioenergetics%2C+and+the+tubular+cell+adaptation+to+injury.&amp;publication_year=2014&amp;journal=Shock&amp;pages=3-11&amp;doi=10.1097%2FSHK.0000000000000052&amp;pmid=24346647" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Rodríguez E, Elia C, Solà E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. <em>J Hepatol</em> 2014;60:955-961.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2013.12.032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24447876/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000334515000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+and+albumin+for+type-1+hepatorenal+syndrome+associated+with+sepsis.&amp;publication_year=2014&amp;journal=J+Hepatol&amp;pages=955-961&amp;doi=10.1016%2Fj.jhep.2013.12.032&amp;pmid=24447876" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Wong F, Pappas SC, Boyer TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome. <em>Clin Gastroenterol Hepatol</em> 2017;15(2):266-272.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2016.07.016" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27464593/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397246400020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+improves+renal+function+and+reverses+hepatorenal+syndrome+in+patients+with+systemic+inflammatory+response+syndrome.&amp;publication_year=2017&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=266-272.e1&amp;doi=10.1016%2Fj.cgh.2016.07.016&amp;pmid=27464593" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. <em>Lancet Gastroenterol Hepatol</em> 2017;2:94-102.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2468-1253(16)30157-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28403995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426978300016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+of+pharmacological+strategies+for+management+of+type+1+hepatorenal+syndrome%3A+a+systematic+review+and+network+meta-analysis.&amp;publication_year=2017&amp;journal=Lancet+Gastroenterol+Hepatol&amp;pages=94-102&amp;doi=10.1016%2FS2468-1253%2816%2930157-1&amp;pmid=28403995" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. <em>Cochrane Database Syst Rev</em> 2012;9:CD005162-CD005162.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22972083/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308829500023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+for+hepatorenal+syndrome.&amp;publication_year=2012&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD005162-CD005162&amp;pmid=22972083" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] kidney function in patients with HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or have been shown to be ineffective. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Hiremath SB, Srinivas LD. Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis. <em>Indian J Pharmacol</em> 2013;45:54-60.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4103/0253-7613.106436" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23543867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000315916200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+benefits+of+terlipressin+and+non-responder+state+in+hepatorenal+syndrome%3A+a+meta-analysis.&amp;publication_year=2013&amp;journal=Indian+J+Pharmacol&amp;pages=54-60&amp;doi=10.4103%2F0253-7613.106436&amp;pmid=23543867" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. <em>Medicine (Baltimore)</em> 2018;97:e0431-e0431.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29668606/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000431517200032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+in+the+treatment+of+hepatorenal+syndrome%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2018&amp;journal=Medicine+%28Baltimore%29&amp;pages=e0431-e0431&amp;pmid=29668606" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. <em>Clin Gastroenterol Hepatol</em> 2018;16(2):162-177.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2017.05.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28602971/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424389900010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+developments+in+hepatorenal+syndrome.&amp;publication_year=2018&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=162-177.e1&amp;doi=10.1016%2Fj.cgh.2017.05.041&amp;pmid=28602971" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Runyon BA. Practice guideline — management of adult patients with ascites due to cirrhosis: Update 2012. Alexandria, VA: American Association for the Study of Liver Diseases, 2012.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Runyon+BA.+Practice+guideline+%E2%80%94+management+of+adult+patients+with+ascites+due+to+cirrhosis%3A+Update+2012.+Alexandria%2C+VA%3A+American+Association+for+the+Study+of+Liver+Diseases%2C+2012." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. <em>Cochrane Database Syst Rev</em> 2017;9:CD011532-CD011532.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28953318/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411959500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+versus+other+vasoactive+drugs+for+hepatorenal+syndrome.&amp;publication_year=2017&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD011532-CD011532&amp;pmid=28953318" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. <em>Hepatology</em> 2015;62:567-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.27709" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25644760/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358453700027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+plus+albumin+versus+midodrine+and+octreotide+plus+albumin+in+the+treatment+of+hepatorenal+syndrome%3A+a+randomized+trial.&amp;publication_year=2015&amp;journal=Hepatology&amp;pages=567-574&amp;doi=10.1002%2Fhep.27709&amp;pmid=25644760" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Narahara Y, Kanazawa H, Taki Y, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. <em>J Gastroenterol Hepatol</em> 2009;24:1791-1797.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1440-1746.2009.05873.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19686420/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000271248000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+terlipressin+on+systemic%2C+hepatic+and+renal+hemodynamics+in+patients+with+cirrhosis.&amp;publication_year=2009&amp;journal=J+Gastroenterol+Hepatol&amp;pages=1791-1797&amp;doi=10.1111%2Fj.1440-1746.2009.05873.x&amp;pmid=19686420" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Krag A, Bendtsen F, Mortensen C, Henriksen JH, Møller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. <em>Eur J Gastroenterol Hepatol</em> 2010;22:1085-1092.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MEG.0b013e32833a4822" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20453655/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280604500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+a+single+terlipressin+administration+on+cardiac+function+and+perfusion+in+cirrhosis.&amp;publication_year=2010&amp;journal=Eur+J+Gastroenterol+Hepatol&amp;pages=1085-1092&amp;doi=10.1097%2FMEG.0b013e32833a4822&amp;pmid=20453655" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Narahara Y, Kanazawa H, Sakamoto C, et al. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. <em>J Gastroenterol</em> 2012;47:313-320.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00535-011-0485-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22038555/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000303455700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+efficacy+and+safety+of+terlipressin+and+albumin+in+patients+with+type+1+hepatorenal+syndrome%3A+a+multicenter%2C+open-label%2C+explorative+study.&amp;publication_year=2012&amp;journal=J+Gastroenterol&amp;pages=313-320&amp;doi=10.1007%2Fs00535-011-0485-8&amp;pmid=22038555" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Kalambokis GN, Pappas K, Tsianos EV. Terlipressin improves pulmonary pressures in cirrhotic patients with pulmonary hypertension and variceal bleeding or hepatorenal syndrome. <em>Hepatobiliary Pancreat Dis Int</em> 2012;11:434-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1499-3872(12)60204-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22893473/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000307210300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+improves+pulmonary+pressures+in+cirrhotic+patients+with+pulmonary+hypertension+and+variceal+bleeding+or+hepatorenal+syndrome.&amp;publication_year=2012&amp;journal=Hepatobiliary+Pancreat+Dis+Int&amp;pages=434-437&amp;doi=10.1016%2FS1499-3872%2812%2960204-5&amp;pmid=22893473" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/9"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">9</span></span> • <span property="datePublished">March 4, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">818</span>-<span property="pageEnd">828</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2008290" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2008290?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 3, 2021</div><div><b class="core-label">Published in issue</b>: March 4, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/clinical-medicine-general" alt="View article keyword Clinical Medicine General" data-interactiontype="article_recirculation_click">Clinical Medicine General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/gastroenterology-general" alt="View article keyword Gastroenterology General" data-interactiontype="article_recirculation_click">Gastroenterology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/liver-disease" alt="View article keyword Liver Disease" data-interactiontype="article_recirculation_click">Liver Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/nephrology-general" alt="View article keyword Nephrology General" data-interactiontype="article_recirculation_click">Nephrology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pulmonary-critical-care-general" alt="View article keyword Pulmonary/Critical Care General" data-interactiontype="article_recirculation_click">Pulmonary/Critical Care General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Florence</span> <span property="familyName">Wong</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">S. Chris</span> <span property="familyName">Pappas</span>, <span property="honorificSuffix">M.D., J.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael P.</span> <span property="familyName">Curry</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">K. Rajender</span> <span property="familyName">Reddy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Raymond A.</span> <span property="familyName">Rubin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael K.</span> <span property="familyName">Porayko</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stevan A.</span> <span property="familyName">Gonzalez</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Khalid</span> <span property="familyName">Mumtaz</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nicholas</span> <span property="familyName">Lim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Douglas A.</span> <span property="familyName">Simonetto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pratima</span> <span property="familyName">Sharma</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Arun J.</span> <span property="familyName">Sanyal</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marlyn J.</span> <span property="familyName">Mayo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">R. Todd</span> <span property="familyName">Frederick</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shannon</span> <span property="familyName">Escalante</span>, <span property="honorificSuffix">M.S.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Khurram</span> <span property="familyName">Jamil</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the CONFIRM Study Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Medicine, University of Toronto, Toronto (F.W.); Orphan Therapeutics, Annandale (S.C.P.), and Mallinckrodt Pharmaceuticals, Bedminster (S.E., K.J.) — both in New Jersey; the Department of Medicine, Beth Israel Deaconess Medical Center, Boston (M.P.C.); the University of Pennsylvania, Philadelphia (K.R.R.); Piedmont Transplant Institute, Piedmont Healthcare, Atlanta (R.A.R.); the Department of Medicine, Vanderbilt University Medical Center, Nashville (M.K.P.); the Department of Medicine, Baylor Scott and White All Saints Medical Center, Fort Worth (S.A.G.), and the Department of Medicine, University of Texas Southwestern Medical Center, Dallas (M.J.M.) — both in Texas; Ohio State University, Columbus (K.M.); the Department of Medicine, University of Minnesota, Minneapolis (N.L.), and the Department of Medicine, Mayo Clinic, Rochester (D.A.S.) — both in Minnesota; the Department of Medicine, University of Michigan Medical Center, Ann Arbor (P.S.); Virginia Commonwealth University, Richmond (A.J.S.); and Hepatology and Liver Transplantation, California Pacific Medical Center, San Francisco (R.T.F.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Wong at the Department of Medicine, University of Toronto, 200 Elizabeth St., Toronto, ON M5G 2C4, Canada, or at <a href="mailto:florence.wong@utoronto.ca">florence.wong@utoronto.ca</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of investigators in the CONFIRM Study are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">336</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2008290" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="8a4f4fa6-fc23-c08b-a4fb-4a0ddd1908c1"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772" style="display:inline-block;">
                <img alt="Article has an altmetric score of 468" src="https://badges.altmetric.com/?size=320&amp;score=468&amp;types=mabctwf1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_8a4f4fa6-fc23-c08b-a4fb-4a0ddd1908c1" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=news">
          Picked up by <b>31</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=blogs">
          Blogged by <b>6</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=twitter">
          Posted by <b>327</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=patents">
          Referenced in <b>3</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=wikipedia">
          Referenced in <b>3</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=guidelines">
          Referenced in <b>5</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101269772&amp;tab=bluesky">
          Referenced by <b>1</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>341</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d66fe6e5cfa538-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2008290"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-9%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2008290%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="336" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">J. Pedro Teixeira, </li><li class="list-inline-item cited-by__entry__author">Constantine J. Karvellas, </li><li class="list-inline-item cited-by__entry__author">Juan Carlos Q. Velez, </li></ul><span class="cited-by__entry__title">The Diagnosis and Management of Hepatorenal Syndrome: A Comprehensive Update for the Intensivist, </span><span class="cited-by__entry__series-title">Journal of Intensive Care Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/08850666251345408" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/08850666251345408</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/08850666251345408" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jeremy Skvarce, </li><li class="list-inline-item cited-by__entry__author">Albert Bui, </li><li class="list-inline-item cited-by__entry__author">Peter Oro, </li><li class="list-inline-item cited-by__entry__author">Saloni Sachar, </li><li class="list-inline-item cited-by__entry__author">Mary Pat Harnegie, </li><li class="list-inline-item cited-by__entry__author">Aanchal Kapoor, </li><li class="list-inline-item cited-by__entry__author">Christina C. Lindenmeyer, </li><li class="list-inline-item cited-by__entry__author">Matthew T. Siuba, </li></ul><span class="cited-by__entry__title">Multisystem hemodynamic effects of terlipressin in cirrhosis: A scoping review, </span><span class="cited-by__entry__series-title">Journal of Critical Care, </span><span class="cited-by__entry__volume"><strong>87</strong>, </span><span class="cited-by__entry__page-range">(155038), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jcrc.2025.155038" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jcrc.2025.155038</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jcrc.2025.155038" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Edoardo Antonucci, </li><li class="list-inline-item cited-by__entry__author">Michael P. Bokoch, </li><li class="list-inline-item cited-by__entry__author">Dieter Adelmann, </li><li class="list-inline-item cited-by__entry__author">Kerstin Kolodzie, </li><li class="list-inline-item cited-by__entry__author">Garrett R. Roll, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Sun, </li><li class="list-inline-item cited-by__entry__author">Matthieu Legrand, </li><li class="list-inline-item cited-by__entry__author">Rishi Kothari, </li></ul><span class="cited-by__entry__title">Vasopressin Is Not Associated With Severe Kidney Injury in Liver Transplantation: A Propensity Score-adjusted Analysis, </span><span class="cited-by__entry__series-title">Transplantation Direct, </span><span class="cited-by__entry__volume"><strong>11</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(e1814), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/TXD.0000000000001814" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/TXD.0000000000001814</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/TXD.0000000000001814" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yujiao Jin, </li><li class="list-inline-item cited-by__entry__author">Miaochan Wang, </li><li class="list-inline-item cited-by__entry__author">Aifang Xu, </li><li class="list-inline-item cited-by__entry__author">Binbin Xu, </li></ul><span class="cited-by__entry__title">Letter to the Editor: Association between mean arterial pressure and terlipressin in the reversal of hepatorenal syndrome-acute kidney injury, </span><span class="cited-by__entry__series-title">Hepatology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/HEP.0000000000001404" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/HEP.0000000000001404</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/HEP.0000000000001404" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sandeep Sikerwar, </li><li class="list-inline-item cited-by__entry__author">Leah Yao, </li><li class="list-inline-item cited-by__entry__author">Yasmine Elfarra, </li><li class="list-inline-item cited-by__entry__author">Arun Jesudian, </li></ul><span class="cited-by__entry__title">Optimal Management of the Inpatient With Decompensated Cirrhosis, </span><span class="cited-by__entry__series-title">Journal of Clinical Gastroenterology, </span><span class="cited-by__entry__volume"><strong>59</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(420-432), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/MCG.0000000000002143" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/MCG.0000000000002143</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/MCG.0000000000002143" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Adrià Juanola, </li><li class="list-inline-item cited-by__entry__author">Ann T. Ma, </li><li class="list-inline-item cited-by__entry__author">Giuseppe Cullaro, </li><li class="list-inline-item cited-by__entry__author">Mariam P. Alexander, </li><li class="list-inline-item cited-by__entry__author">Andrew S. Allegretti, </li><li class="list-inline-item cited-by__entry__author">Pere Ginès, </li></ul><span class="cited-by__entry__title">Development of Acute Kidney Injury in a Patient With Alcohol-related Cirrhosis: The Importance of Diagnosing the Cause of Acute Kidney Injury, </span><span class="cited-by__entry__series-title">Gastroenterology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1053/j.gastro.2025.03.056" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1053/j.gastro.2025.03.056</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1053/j.gastro.2025.03.056" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Karen Vagner Danielsen, </li><li class="list-inline-item cited-by__entry__author">Jens Dahlgaard Hove, </li><li class="list-inline-item cited-by__entry__author">Puria Nabilou, </li><li class="list-inline-item cited-by__entry__author">Thit Mynster Kronborg, </li><li class="list-inline-item cited-by__entry__author">Signe Wiese, </li><li class="list-inline-item cited-by__entry__author">Hartwig Roman Siebner, </li><li class="list-inline-item cited-by__entry__author">Robert Scott, </li><li class="list-inline-item cited-by__entry__author">Susan T. Francis, </li><li class="list-inline-item cited-by__entry__author">Guruprasad P. Aithal, </li><li class="list-inline-item cited-by__entry__author">Søren Møller, </li><li class="list-inline-item cited-by__entry__author">Flemming Bendtsen, </li></ul><span class="cited-by__entry__title">Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging, </span><span class="cited-by__entry__series-title">JHEP Reports, </span><span class="cited-by__entry__page-range">(101452), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jhepr.2025.101452" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jhepr.2025.101452</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jhepr.2025.101452" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Tarana Gupta, </li><li class="list-inline-item cited-by__entry__author">Anjali Saini, </li><li class="list-inline-item cited-by__entry__author">Vaibhav Gaur, </li><li class="list-inline-item cited-by__entry__author">Ashank Goel, </li></ul><span class="cited-by__entry__title">Comparative Study of Terlipressin and Noradrenaline as Vasopressors in Patients With Acute-on-chronic Liver Failure and Septic Shock: A Randomized Controlled Trial, </span><span class="cited-by__entry__series-title">Journal of Clinical and Experimental Hepatology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(102494), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jceh.2024.102494" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jceh.2024.102494</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jceh.2024.102494" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Adily N. Elmi, </li><li class="list-inline-item cited-by__entry__author">Paul Y. Kwo, </li></ul><span class="cited-by__entry__title">The Liver in Sepsis, </span><span class="cited-by__entry__series-title">Clinics in Liver Disease, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.cld.2025.04.002" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.cld.2025.04.002</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.cld.2025.04.002" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shilpa Junna, </li><li class="list-inline-item cited-by__entry__author">Sarah Nasser, </li><li class="list-inline-item cited-by__entry__author">Pratima Sharma, </li></ul><span class="cited-by__entry__title">Renal Dysfunction and Liver Transplantation, </span><span class="cited-by__entry__series-title">Clinics in Liver Disease, </span><span class="cited-by__entry__volume"><strong>29</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(273-285), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.cld.2024.12.009" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.cld.2024.12.009</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.cld.2024.12.009" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-9%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2008290%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2008290" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2008290" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2008290.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2008290_f1.jpg"><img src="/cms/10.1056/NEJMoa2008290/asset/e61d9109-6b56-4195-aaaf-975a9aa48752/assets/images/large/nejmoa2008290_f1.jpg" height="3405" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">The categories of “withdrew consent” and “had other reason for end of follow-up” are not cumulative; the categories of “lost to follow-up” and “died” are cumulative. Some patients had more than one reason for ending follow-up. Among the reasons for the end of the treatment period of up to 14 days, the category of “died” in the terlipressin group applies to 4 patients who died during the time they were receiving the drug. A total of 9 patients in the terlipressin group and 1 patient in the placebo group died during the on-treatment period (defined as the period from the first dose up to 24 hours after discontinuation of the regimen). The patients who died within 24 hours after discontinuation of the regimen were included in the category “had other reason.” HRS denotes hepatorenal syndrome, and TIPS transjugular intrahepatic portosystemic shunt.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2008290_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2008290/asset/83108354-012a-45da-92cb-1b22d4e66dd3/assets/images/large/nejmoa2008290_t1.jpg" height="2157" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Terlipressin<br>(N=199)</th><th class="txxr-borders">Placebo<br>(N=101)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">54.0±11.3</td><td class="xxxr-borders shading">53.6±11.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">120 (60)</td><td class="xxxr-borders">59 (58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Cause of liver cirrhosis — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Alcohol use</td><td class="xxxx-borders">134 (67)</td><td class="xxxr-borders">67 (66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonalcoholic steatohepatitis</td><td class="xxxx-borders shading">42 (21)</td><td class="xxxr-borders shading">24 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Viral hepatitis</td><td class="xxxx-borders">35 (18)</td><td class="xxxr-borders">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Autoimmune hepatitis</td><td class="xxxx-borders shading">10 (5)</td><td class="xxxr-borders shading">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Primary biliary cirrhosis</td><td class="xxxx-borders">5 (3)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other cause or cryptogenic liver disease</td><td class="xxxx-borders shading">15 (8)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Alcoholic hepatitis — no. (%)</td><td class="xxxx-borders">81 (41)</td><td class="xxxr-borders">39 (39)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Systemic inflammatory response syndrome — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">84 (42)</td><td class="xxxr-borders shading">48 (48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Mean arterial pressure — mm Hg</td><td class="xxxx-borders">78.7±12.1</td><td class="xxxr-borders">77.5±9.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serum sodium level — mmol/liter</td><td class="xxxx-borders shading">133.1±5.6</td><td class="xxxr-borders shading">133.3±5.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serum creatinine level — mg/dl</td><td class="xxxx-borders">3.5±1.0</td><td class="xxxr-borders">3.5±1.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Total bilirubin level — mg/dl</td><td class="xxxx-borders shading">13.1±13.5</td><td class="xxxr-borders shading">15.0±15.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Albumin level — g/dl</td><td class="xxxx-borders">3.7±0.7</td><td class="xxxr-borders">4.0±2.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Child–Pugh score<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">10.0±1.85</td><td class="xxxr-borders shading">10.2±1.89</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">MELD score<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xbxx-borders">32.7±6.6</td><td class="xbxr-borders">33.1±6.2</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. To convert the values for bilirubin to micromoles per liter, multiply by 17.1. To convert the values for serum creatinine to micromoles per liter, multiply by 88.4.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Systemic inflammatory response syndrome is diagnosed when two or more of the following criteria are met: body temperature lower than 36°C or higher than 38°C; heart rate greater than 90 beats per minute; respiratory rate greater than 20 breaths per minute or partial pressure of arterial carbon dioxide lower than 4.3 kPa (32 mm Hg); white-cell count lower than 4000 cells per cubic millimeter or higher than 12,000 cells per cubic millimeter; or the presence of more than 10% immature neutrophils (band forms).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The Child–Pugh score is based on five clinical measures of liver function (total bilirubin level, serum albumin level, prothrombin time, ascites, and hepatic encephalopathy, with each measure graded according to severity); scores range from 5 to 15, with higher scores indicating more advanced liver disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The Model of End-Stage Liver Disease (MELD) score is based on the international normalized ratio for prothrombin time (INR) and serum bilirubin and creatinine levels and is calculated as follows: [3.78×ln(serum bilirubin in milligrams per deciliter)]+[11.2×ln(INR)]+[9.57×ln(serum creatinine in milligrams per deciliter)]+6.43, where ln is natural log. Scores range from 6 to 40, with higher scores indicating more severe disease, and have been shown to be predictive of survival in a wide variety of patients with cirrhosis.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2008290/asset/1b188629-4b46-4e38-929b-2bf7616a1892/assets/images/large/nejmoa2008290_t2.jpg" height="2795" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Terlipressin</th><th class="txxx-borders">Placebo</th><th class="txxr-borders">P Value</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>number/total number of patients (percent)</span></th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Primary end point of verified reversal of HRS</b><a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">0.006</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Clinical success</td><td class="xxxx-borders">63/199 (32)</td><td class="xxxx-borders">17/101 (17)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Clinical failure</td><td class="xxxx-borders shading">121/199 (61)</td><td class="xxxx-borders shading">81/101 (80)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Competing event<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders shading">10/199 (5)</td><td class="xxxx-borders shading">2/101 (2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death</td><td class="xxxx-borders">5/199 (3)</td><td class="xxxx-borders">0/101</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Secondary end points included in multiplicity adjustment</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HRS reversal<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">78/199 (39)</td><td class="xxxx-borders shading">18/101 (18)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">105/199 (53)</td><td class="xxxx-borders">79/101 (78)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">11/199 (6)</td><td class="xxxx-borders">4/101 (4)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">5/199 (3)</td><td class="xxxx-borders shading">0/101</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HRS reversal with no renal-replacement therapy through 30 days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">68/199 (34)</td><td class="xxxx-borders shading">17/101 (17)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">116/199 (58)</td><td class="xxxx-borders">80/101 (79)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">10/199 (5)</td><td class="xxxx-borders">3/101 (3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">5/199 (3)</td><td class="xxxx-borders shading">0/101</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HRS reversal in patients with systemic inflammatory response syndrome</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">31/84 (37)</td><td class="xxxx-borders shading">3/48 (6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">45/84 (54)</td><td class="xxxx-borders">43/48 (90)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">4/84 (5)</td><td class="xxxx-borders">1/48 (2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">5/84 (6)</td><td class="xxxx-borders shading">0/48</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Verified reversal of HRS with no recurrence through 30 days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.08</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Clinical success</td><td class="xxxx-borders shading">52/199 (26)</td><td class="xxxx-borders shading">17/101 (17)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Clinical failure</td><td class="xxxx-borders">131/199 (66)</td><td class="xxxx-borders">81/101 (80)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Competing event<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver transplantation</td><td class="xxxx-borders">10/199 (5)</td><td class="xxxx-borders">2/101 (2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23 shading" data-xml-align="left">Death</td><td class="xbxx-borders shading">5/199 (3)</td><td class="xbxx-borders shading">0/101</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Efficacy analyses were performed in the intention-to-treat population, which included all patients who underwent randomization. Because of multiple imputation, the total number of patients in a trial group who had clinical success, clinical failure, or a competing event with respect to each end point is either 1 less or 1 greater than the total number of patients listed in that trial group. The numbers imputed for the primary end point of verified hepatorenal syndrome (HRS) reversal were 17 in the terlipressin group and 9 in the placebo group; for HRS reversal, 16 and 8, respectively; for HRS reversal with no renal-replacement therapy through 30 days, 6 and 6, respectively; for HRS reversal in patients with systemic inflammatory response syndrome, 8 and 3, respectively; and for verified reversal of HRS with no recurrence through 30 days, 17 and 9, respectively.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Verified reversal of HRS was defined as two consecutive serum creatinine measurements of 1.5 mg per deciliter (133 μmol per liter) or less at least 2 hours apart and survival without renal-replacement therapy for at least 10 days.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Competing events included deaths or liver transplantations that occurred before the patient met the criteria for clinical success or failure. The reported numbers of competing events involving deaths and liver transplantations include outcomes that were assigned on the basis of multiple imputation.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">HRS reversal was defined as any serum creatinine level of 1.5 mg per deciliter or less while receiving terlipressin or placebo.</div></div></div></figcaption></a><figcaption><div class="caption">Primary and Four Secondary End Points Included in Multiplicity Adjustment.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2008290/asset/074cf611-4811-4726-a5d1-118018bee30b/assets/images/large/nejmoa2008290_t3.jpg" height="1389" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Terlipressin<br>(N=199)</th><th class="txxr-borders">Placebo<br>(N=101)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Received renal-replacement therapy</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 14</td><td class="xxxx-borders">45 (23)</td><td class="xxxr-borders">35 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 30</td><td class="xxxx-borders shading">51 (26)</td><td class="xxxr-borders shading">36 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 60</td><td class="xxxx-borders">56 (28)</td><td class="xxxr-borders">38 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 90</td><td class="xxxx-borders shading">58 (29)</td><td class="xxxr-borders shading">39 (39)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Underwent liver transplantation</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 14</td><td class="xxxx-borders shading">19 (10)</td><td class="xxxr-borders shading">15 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 30</td><td class="xxxx-borders">32 (16)</td><td class="xxxr-borders">22 (22)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 60</td><td class="xxxx-borders shading">43 (22)</td><td class="xxxr-borders shading">28 (28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 90</td><td class="xxxx-borders">46 (23)</td><td class="xxxr-borders">29 (29)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Died</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 14</td><td class="xxxx-borders">53 (27)</td><td class="xxxr-borders">24 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Day 30</td><td class="xxxx-borders shading">78 (39)</td><td class="xxxr-borders shading">36 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Day 60</td><td class="xxxx-borders">91 (46)</td><td class="xxxr-borders">41 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Day 90</td><td class="xbxx-borders shading">101 (51)</td><td class="xbxr-borders shading">45 (45)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The number of deaths or liver transplantations up to day 30 includes those classified as competing events and those that occurred after a patient met the criteria for clinical success or failure.</div></div></div></figcaption></a><figcaption><div class="caption">Additional Secondary End Points Assessed at Days 14, 30, 60, and 90.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t4"><figure class="table"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t4.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2008290/asset/ff44b46b-90d6-4edb-b39a-aa89db43bd1b/assets/images/large/nejmoa2008290_t4.jpg" height="2527" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Terlipressin<br>(N=200)</th><th class="txxr-borders">Placebo<br>(N=99)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse events of any grade<a href="#core-t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">176 (88)</td><td class="xxxr-borders shading">88 (89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Adverse events leading to discontinuation of the trial regimen</td><td class="xxxx-borders">24 (12)</td><td class="xxxr-borders">5 (5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Serious adverse events with an incidence of ≥3% in either trial group<a href="#core-t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Any</td><td class="xxxx-borders">130 (65)</td><td class="xxxr-borders">60 (61)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Cardiac disorders</td><td class="xxxx-borders shading">8 (4)</td><td class="xxxr-borders shading">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Atrial fibrillation</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Gastrointestinal disorders</td><td class="xxxx-borders shading">30 (15)</td><td class="xxxr-borders shading">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">10 (5)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Gastrointestinal hemorrhage</td><td class="xxxx-borders shading">8 (4)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">General disorders and administration-site conditions</td><td class="xxxx-borders">11 (6)</td><td class="xxxr-borders">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Multiple organ dysfunction syndrome</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hepatobiliary disorders</td><td class="xxxx-borders">37 (18)</td><td class="xxxr-borders">29 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Chronic hepatic failure</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Alcoholic cirrhosis</td><td class="xxxx-borders">4 (2)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Hepatic cirrhosis</td><td class="xxxx-borders shading">6 (3)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hepatic failure</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">10 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Worsening of HRS</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Infections and infestations</td><td class="xxxx-borders">19 (10)</td><td class="xxxr-borders">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">4 (2)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Sepsis</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nervous system disorders</td><td class="xxxx-borders shading">13 (6)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hepatic encephalopathy</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Respiratory, thoracic, and mediastinal disorders<a href="#core-t4fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">33 (16)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Acute respiratory failure</td><td class="xxxx-borders">8 (4)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Respiratory failure</td><td class="xxxx-borders shading">20 (10)</td><td class="xxxr-borders shading">3 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Vascular disorders</td><td class="xxxx-borders">10 (5)</td><td class="xxxr-borders">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23 shading" data-xml-align="left">Shock</td><td class="xbxx-borders shading">5 (2)</td><td class="xbxr-borders shading">3 (3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t4fn1" role="paragraph" data-to-manipulate="true">The safety population included all patients who underwent randomization and received at least one dose of terlipressin or placebo. For each event category, the patients were counted once even if they had multiple events in that category. One patient in the placebo group did not receive a first dose, and one patient who had been assigned to receive placebo inadvertently received one dose of terlipressin and was therefore assigned to the terlipressin group in the safety analysis.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t4fn2" role="paragraph" data-to-manipulate="true">The numbers of events include those that occurred up to 7 days after the end of the treatment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t4fn3" role="paragraph" data-to-manipulate="true">The numbers of events include those that occurred up to 30 days after the end of the treatment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t4fn4" role="paragraph" data-to-manipulate="true">The numbers reported for acute respiratory failure or respiratory failure are for patients with the condition as coded by the investigator; there is no overlap.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events in the Safety Population.<a href="#core-t4fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t4"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2008290_t4.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2008290</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <em>Gut</em> 2007;56:1310-1318.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17389705/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248725600025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis%2C+prevention+and+treatment+of+hepatorenal+syndrome+in+cirrhosis.&amp;publication_year=2007&amp;journal=Gut&amp;pages=1310-1318&amp;pmid=17389705" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with decompensated cirrhosis and ascites. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] day 1 and 20 to 40 g per day thereafter). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. <em>Aliment Pharmacol Ther</em> 2017;45:1390-1402.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/apt.14052" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28370090/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400785900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Reversal+of+hepatorenal+syndrome+type+1+with+terlipressin+plus+albumin+vs.+placebo+plus+albumin+in+a+pooled+analysis+of+the+OT-0401+and+REVERSE+randomised+clinical+studies.&amp;publication_year=2017&amp;journal=Aliment+Pharmacol+Ther&amp;pages=1390-1402&amp;doi=10.1111%2Fapt.14052&amp;pmid=28370090" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. <em>Nat Rev Dis Primers</em> 2018;4:23-23.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41572-018-0022-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30213943/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444654600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hepatorenal+syndrome.&amp;publication_year=2018&amp;journal=Nat+Rev+Dis+Primers&amp;pages=23-23&amp;doi=10.1038%2Fs41572-018-0022-7&amp;pmid=30213943" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] duration of survival of weeks to months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] renal hemodynamics in these patients. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Zheng J-N, Han Y-J, Zou T-T, et al. Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. <em>Expert Rev Gastroenterol Hepatol</em> 2017;11:1009-1018.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/17474124.2017.1356223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28708431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414938300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+of+vasoconstrictor+therapies+for+type+1+hepatorenal+syndrome%3A+a+network+meta-analysis.&amp;publication_year=2017&amp;journal=Expert+Rev+Gastroenterol+Hepatol&amp;pages=1009-1018&amp;doi=10.1080%2F17474124.2017.1356223&amp;pmid=28708431" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] duration of survival of weeks to months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and function in patients with HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] kidney function in patients with HRS-1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Jamil K, Pappas SC, Devarakonda KR. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V<sub>1</sub> and V<sub>2</sub>. <em>J Exp Pharmacol</em> 2017;10:1-7.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/JEP.S146034" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29302194/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+vitro+binding+and+receptor-mediated+activity+of+terlipressin+at+vasopressin+receptors+V1+and+V2.&amp;publication_year=2017&amp;journal=J+Exp+Pharmacol&amp;pages=1-7&amp;doi=10.2147%2FJEP.S146034&amp;pmid=29302194" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Møller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. <em>Scand J Gastroenterol</em> 2004;39:486-492.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/00365520310008728" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15180188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000221184700014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+terlipressin+on+blood+volume+distribution+in+patients+with+cirrhosis.&amp;publication_year=2004&amp;journal=Scand+J+Gastroenterol&amp;pages=486-492&amp;doi=10.1080%2F00365520310008728&amp;pmid=15180188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. <em>Crit Care Med</em> 2011;39:1329-1334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0b013e3182120842" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21336108/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290715000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+use+of+terlipressin+during+living+donor+liver+transplantation%3A+effects+on+systemic+and+splanchnic+hemodynamics+and+renal+function.&amp;publication_year=2011&amp;journal=Crit+Care+Med&amp;pages=1329-1334&amp;doi=10.1097%2FCCM.0b013e3182120842&amp;pmid=21336108" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. <em>Gastroenterology</em> 2008;134:1360-1368.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2008.02.014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18471513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255676700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized%2C+prospective%2C+double-blind%2C+placebo-controlled+trial+of+terlipressin+for+type+1+hepatorenal+syndrome.&amp;publication_year=2008&amp;journal=Gastroenterology&amp;pages=1360-1368&amp;doi=10.1053%2Fj.gastro.2008.02.014&amp;pmid=18471513" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] placebo-controlled trials of varying sizes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] previous trials of terlipressin for HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and North America. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] kidney function in patients with HRS-1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Martín-Llahí M, Pépin M-N, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. <em>Gastroenterology</em> 2008;134:1352-1359.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2008.02.024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18471512/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255676700015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+and+albumin+vs+albumin+in+patients+with+cirrhosis+and+hepatorenal+syndrome%3A+a+randomized+study.&amp;publication_year=2008&amp;journal=Gastroenterology&amp;pages=1352-1359&amp;doi=10.1053%2Fj.gastro.2008.02.024&amp;pmid=18471512" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] placebo-controlled trials of varying sizes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were similar to those of trials from Europe </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. <em>Gastroenterology</em> 2016;150(7):1579-1589.e2.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2016.02.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26896734/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376778800030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+plus+albumin+is+more+effective+than+albumin+alone+in+improving+renal+function+in+patients+with+cirrhosis+and+hepatorenal+syndrome+type+1.&amp;publication_year=2016&amp;journal=Gastroenterology&amp;pages=1579-1589.e2&amp;doi=10.1053%2Fj.gastro.2016.02.026&amp;pmid=26896734" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] placebo-controlled trials of varying sizes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] previous trials of terlipressin for HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and North America. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] kidney function in patients with HRS-1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Papaluca T, Gow P. Terlipressin: current and emerging indications in chronic liver disease. <em>J Gastroenterol Hepatol</em> 2018;33:591-598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/jgh.14009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28981166/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425735300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin%3A+current+and+emerging+indications+in+chronic+liver+disease.&amp;publication_year=2018&amp;journal=J+Gastroenterol+Hepatol&amp;pages=591-598&amp;doi=10.1111%2Fjgh.14009&amp;pmid=28981166" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. <em>J Hepatol</em> 2018;69:406-460.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2018.03.024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29653741/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438753600020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EASL+clinical+practice+guidelines+for+the+management+of+patients+with+decompensated+cirrhosis.&amp;publication_year=2018&amp;journal=J+Hepatol&amp;pages=406-460&amp;doi=10.1016%2Fj.jhep.2018.03.024&amp;pmid=29653741" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Special protocol assessment: guidance for industry. April 2018 (<a href="https://www.fda.gov/media/97618/download">https://www.fda.gov/media/97618/download</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Food+and+Drug+Administration.+Special+protocol+assessment%3A+guidance+for+industry.+April+2018+%28https%3A%2F%2Fwww.fda.gov%2Fmedia%2F97618%2Fdownload%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] as a phase 3 registration trial </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of at least a doubling within 2 weeks. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Jamil K, Pappas SC, Wong F, Sanyal AJ. Verified hepatorenal syndrome reversal as a robust multi-component primary end point: the CONFIRM study trial design. <em>J Clin Trials</em> 2019;11:67-73.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Verified+hepatorenal+syndrome+reversal+as+a+robust+multi-component+primary+end+point%3A+the+CONFIRM+study+trial+design.&amp;publication_year=2019&amp;journal=J+Clin+Trials&amp;pages=67-73" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <em>J Hepatol</em> 2015;62:968-974.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2014.12.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25638527/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000351305300029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis+and+management+of+acute+kidney+injury+in+patients+with+cirrhosis%3A+revised+consensus+recommendations+of+the+International+Club+of+Ascites.&amp;publication_year=2015&amp;journal=J+Hepatol&amp;pages=968-974&amp;doi=10.1016%2Fj.jhep.2014.12.029&amp;pmid=25638527" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] day 1 and 20 to 40 g per day thereafter). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which eliminates end-stage liver disease, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Allegretti AS, Vela Parada X, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. <em>Clin J Am Soc Nephrol</em> 2018;13:16-25.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2215/CJN.03610417" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29122911/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419758100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prognosis+of+patients+with+cirrhosis+and+AKI+who+initiate+RRT.&amp;publication_year=2018&amp;journal=Clin+J+Am+Soc+Nephrol&amp;pages=16-25&amp;doi=10.2215%2FCJN.03610417&amp;pmid=29122911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Piano S, Brocca A, Angeli P. Renal function in cirrhosis: a critical review of available tools. <em>Semin Liver Dis</em> 2018;38:230-241.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0038-1661372" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30041275/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439917800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Renal+function+in+cirrhosis%3A+a+critical+review+of+available+tools.&amp;publication_year=2018&amp;journal=Semin+Liver+Dis&amp;pages=230-241&amp;doi=10.1055%2Fs-0038-1661372&amp;pmid=30041275" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Reiberger T. When should we stop treatment with terlipressin and albumin for patients with hepatorenal syndrome? <em>Clin Gastroenterol Hepatol</em> 2018;16:1710-1711.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2018.04.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29684461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000447826300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=When+should+we+stop+treatment+with+terlipressin+and+albumin+for+patients+with+hepatorenal+syndrome%3F&amp;publication_year=2018&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=1710-1711&amp;doi=10.1016%2Fj.cgh.2018.04.020&amp;pmid=29684461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. <em>Kidney Int</em> 2015;87:509-515.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ki.2014.338" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25296092/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350533300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Renal+dysfunction+in+cirrhosis+is+not+just+a+vasomotor+nephropathy.&amp;publication_year=2015&amp;journal=Kidney+Int&amp;pages=509-515&amp;doi=10.1038%2Fki.2014.338&amp;pmid=25296092" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. <em>Shock</em> 2014;41:3-11.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/SHK.0000000000000052" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24346647/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336209200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+unified+theory+of+sepsis-induced+acute+kidney+injury%3A+inflammation%2C+microcirculatory+dysfunction%2C+bioenergetics%2C+and+the+tubular+cell+adaptation+to+injury.&amp;publication_year=2014&amp;journal=Shock&amp;pages=3-11&amp;doi=10.1097%2FSHK.0000000000000052&amp;pmid=24346647" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Rodríguez E, Elia C, Solà E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. <em>J Hepatol</em> 2014;60:955-961.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2013.12.032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24447876/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000334515000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+and+albumin+for+type-1+hepatorenal+syndrome+associated+with+sepsis.&amp;publication_year=2014&amp;journal=J+Hepatol&amp;pages=955-961&amp;doi=10.1016%2Fj.jhep.2013.12.032&amp;pmid=24447876" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Wong F, Pappas SC, Boyer TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome. <em>Clin Gastroenterol Hepatol</em> 2017;15(2):266-272.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2016.07.016" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27464593/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397246400020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+improves+renal+function+and+reverses+hepatorenal+syndrome+in+patients+with+systemic+inflammatory+response+syndrome.&amp;publication_year=2017&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=266-272.e1&amp;doi=10.1016%2Fj.cgh.2016.07.016&amp;pmid=27464593" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. <em>Lancet Gastroenterol Hepatol</em> 2017;2:94-102.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2468-1253(16)30157-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28403995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426978300016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+of+pharmacological+strategies+for+management+of+type+1+hepatorenal+syndrome%3A+a+systematic+review+and+network+meta-analysis.&amp;publication_year=2017&amp;journal=Lancet+Gastroenterol+Hepatol&amp;pages=94-102&amp;doi=10.1016%2FS2468-1253%2816%2930157-1&amp;pmid=28403995" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. <em>Cochrane Database Syst Rev</em> 2012;9:CD005162-CD005162.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22972083/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308829500023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+for+hepatorenal+syndrome.&amp;publication_year=2012&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD005162-CD005162&amp;pmid=22972083" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] kidney function in patients with HRS-1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or have been shown to be ineffective. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Hiremath SB, Srinivas LD. Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis. <em>Indian J Pharmacol</em> 2013;45:54-60.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4103/0253-7613.106436" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23543867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000315916200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+benefits+of+terlipressin+and+non-responder+state+in+hepatorenal+syndrome%3A+a+meta-analysis.&amp;publication_year=2013&amp;journal=Indian+J+Pharmacol&amp;pages=54-60&amp;doi=10.4103%2F0253-7613.106436&amp;pmid=23543867" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. <em>Medicine (Baltimore)</em> 2018;97:e0431-e0431.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29668606/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000431517200032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+in+the+treatment+of+hepatorenal+syndrome%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2018&amp;journal=Medicine+%28Baltimore%29&amp;pages=e0431-e0431&amp;pmid=29668606" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. <em>Clin Gastroenterol Hepatol</em> 2018;16(2):162-177.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2017.05.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28602971/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424389900010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+developments+in+hepatorenal+syndrome.&amp;publication_year=2018&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=162-177.e1&amp;doi=10.1016%2Fj.cgh.2017.05.041&amp;pmid=28602971" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Runyon BA. Practice guideline — management of adult patients with ascites due to cirrhosis: Update 2012. Alexandria, VA: American Association for the Study of Liver Diseases, 2012.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Runyon+BA.+Practice+guideline+%E2%80%94+management+of+adult+patients+with+ascites+due+to+cirrhosis%3A+Update+2012.+Alexandria%2C+VA%3A+American+Association+for+the+Study+of+Liver+Diseases%2C+2012." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. <em>Cochrane Database Syst Rev</em> 2017;9:CD011532-CD011532.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28953318/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411959500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+versus+other+vasoactive+drugs+for+hepatorenal+syndrome.&amp;publication_year=2017&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD011532-CD011532&amp;pmid=28953318" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. <em>Hepatology</em> 2015;62:567-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.27709" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25644760/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358453700027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+plus+albumin+versus+midodrine+and+octreotide+plus+albumin+in+the+treatment+of+hepatorenal+syndrome%3A+a+randomized+trial.&amp;publication_year=2015&amp;journal=Hepatology&amp;pages=567-574&amp;doi=10.1002%2Fhep.27709&amp;pmid=25644760" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Narahara Y, Kanazawa H, Taki Y, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. <em>J Gastroenterol Hepatol</em> 2009;24:1791-1797.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1440-1746.2009.05873.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19686420/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000271248000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+terlipressin+on+systemic%2C+hepatic+and+renal+hemodynamics+in+patients+with+cirrhosis.&amp;publication_year=2009&amp;journal=J+Gastroenterol+Hepatol&amp;pages=1791-1797&amp;doi=10.1111%2Fj.1440-1746.2009.05873.x&amp;pmid=19686420" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Krag A, Bendtsen F, Mortensen C, Henriksen JH, Møller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. <em>Eur J Gastroenterol Hepatol</em> 2010;22:1085-1092.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MEG.0b013e32833a4822" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20453655/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280604500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+a+single+terlipressin+administration+on+cardiac+function+and+perfusion+in+cirrhosis.&amp;publication_year=2010&amp;journal=Eur+J+Gastroenterol+Hepatol&amp;pages=1085-1092&amp;doi=10.1097%2FMEG.0b013e32833a4822&amp;pmid=20453655" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Narahara Y, Kanazawa H, Sakamoto C, et al. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. <em>J Gastroenterol</em> 2012;47:313-320.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00535-011-0485-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22038555/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000303455700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+efficacy+and+safety+of+terlipressin+and+albumin+in+patients+with+type+1+hepatorenal+syndrome%3A+a+multicenter%2C+open-label%2C+explorative+study.&amp;publication_year=2012&amp;journal=J+Gastroenterol&amp;pages=313-320&amp;doi=10.1007%2Fs00535-011-0485-8&amp;pmid=22038555" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Kalambokis GN, Pappas K, Tsianos EV. Terlipressin improves pulmonary pressures in cirrhotic patients with pulmonary hypertension and variceal bleeding or hepatorenal syndrome. <em>Hepatobiliary Pancreat Dis Int</em> 2012;11:434-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1499-3872(12)60204-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22893473/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000307210300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Terlipressin+improves+pulmonary+pressures+in+cirrhotic+patients+with+pulmonary+hypertension+and+variceal+bleeding+or+hepatorenal+syndrome.&amp;publication_year=2012&amp;journal=Hepatobiliary+Pancreat+Dis+Int&amp;pages=434-437&amp;doi=10.1016%2FS1499-3872%2812%2960204-5&amp;pmid=22893473" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 03, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2034425" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Terlipressin and Intravenous Albumin in Advanced Cirrhosis — Friend and Foe</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G. Garcia-Tsao</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 09, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2105498" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Pittsfield, Massachusetts</span></div><div><span>Emergency Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/865666/emergency-medicine-physician/?query=fjwp&amp;rid=886">Emergency Medicine Physician</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887307/therapeutic-gastroenterology-opportunity-live-and-work-on-cape-cod/?query=fjwp&amp;rid=3510">Therapeutic Gastroenterology Opportunity - Live and Work on Cape Cod</a></div></div><div class="nejm-widget_item"><div><span> Janesville, Wisconsin</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885095/full-time-anesthesiologist-needed-in-janesville-wi-/?query=fjwf&amp;rid=196467">Full time Anesthesiologist needed in Janesville, WI!</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Maternal-Fetal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/785024/obgyn-maternal-fetal-medicine-northern-westchester-ny-/?query=fjwp&amp;rid=3059">OBGYN - Maternal Fetal Medicine - (Northern Westchester, NY) </a></div></div><div class="nejm-widget_item"><div><span> New Brunswick, New Jersey</span></div><div><span>Pulmonary Disease</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/882857/academic-chief-of-pulmonary-disease-and-critical-care-medicine/?query=fjwp&amp;rid=560010">ACADEMIC CHIEF OF PULMONARY DISEASE AND CRITICAL CARE MEDICINE</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889671/internal-medicine-physician-350000-00/?query=fjwf&amp;rid=346908">Internal Medicine Physician - $350000.00</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2008290&amp;pubId=41290255&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d66fe6e5cfa538-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d66fe6e5cfa538-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d66fe6e5cfa538-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$576410803$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$576410803$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$576410803$--></div></div><div class="mlt-body"><!--?lit$576410803$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$576410803$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$576410803$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$576410803$-->Feb 23, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2215289?query=recirc_Semantic" target="_self">Acute Kidney Injury in Patients with Cirrhosis</a></div><div class="mlt-article-authors"><!--?lit$576410803$-->M.K. Nadim and G. Garcia-Tsao</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$576410803$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$576410803$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$576410803$-->Jul 16, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2000741?query=recirc_Semantic" target="_self">Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury</a></div><div class="mlt-article-authors"><!--?lit$576410803$-->The STARRT-AKI Investigators</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$576410803$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$576410803$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$576410803$-->May 19, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2503643?query=recirc_Semantic" target="_self">Nerandomilast in Patients with Progressive Pulmonary Fibrosis</a></div><div class="mlt-article-authors"><!--?lit$576410803$-->T.M. Maher and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$576410803$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$576410803$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$576410803$-->May 18, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2414108?query=recirc_Semantic" target="_self">Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis</a></div><div class="mlt-article-authors"><!--?lit$576410803$-->L. Richeldi and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$576410803$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$576410803$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$576410803$-->Apr 03, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405333?query=recirc_Semantic" target="_self">The Genetic Architecture of Congenital Diarrhea and Enteropathy</a></div><div class="mlt-article-authors"><!--?lit$576410803$-->Z. Gaibee and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2008290?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2008290" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2008290.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2008290"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2022166" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2026982" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2008290_f1.jpg"><img src="/cms/10.1056/NEJMoa2008290/asset/e61d9109-6b56-4195-aaaf-975a9aa48752/assets/images/large/nejmoa2008290_f1.jpg" height="3405" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">The categories of “withdrew consent” and “had other reason for end of follow-up” are not cumulative; the categories of “lost to follow-up” and “died” are cumulative. Some patients had more than one reason for ending follow-up. Among the reasons for the end of the treatment period of up to 14 days, the category of “died” in the terlipressin group applies to 4 patients who died during the time they were receiving the drug. A total of 9 patients in the terlipressin group and 1 patient in the placebo group died during the on-treatment period (defined as the period from the first dose up to 24 hours after discontinuation of the regimen). The patients who died within 24 hours after discontinuation of the regimen were included in the category “had other reason.” HRS denotes hepatorenal syndrome, and TIPS transjugular intrahepatic portosystemic shunt.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Four Secondary End Points Included in Multiplicity Adjustment.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Additional Secondary End Points Assessed at Days 14, 30, 60, and 90.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t4" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 4</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events in the Safety Population.<a href="#fv-t4fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/9" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 9</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 04, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2031994" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.C. Kalil and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 04, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2026982" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.K. Choueiri and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 04, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra2027612" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Diffuse Large B-Cell Lymphoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L.H. Sehn and G. Salles</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2008290%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2008290&amp;pubId=41290255&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2008290%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2008290&amp;pubId=41290255&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id05927627133760702" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d66fe6e5cfa538-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d66fe6e5cfa538-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d66fe6e5cfa538-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d66fe6e5cfa538-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d66fe6e5cfa538-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d66fe6e5cfa538-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d66fe6e5cfa538-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d66fe6e5cfa538-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d66fe6e5cfa538-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d66fe6e5cfa538-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d66fe6db98a538',t:'MTc0OTUzMzAxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d66fe6db98a538&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-transactionid="d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" id="captureIFrame_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" target="captureIFrame_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="capture_screen"><input id="capture_signIn_js_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="js_version"><input id="capture_signIn_transactionId_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" type="hidden" class="capture_transactionId_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="capture_transactionId"><input id="capture_signIn_form_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="form"><input id="capture_signIn_flow_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="flow"><input id="capture_signIn_client_id_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="client_id"><input id="capture_signIn_redirect_uri_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="redirect_uri"><input id="capture_signIn_response_type_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="response_type"><input id="capture_signIn_flow_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="flow_version"><input id="capture_signIn_settings_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="settings_version"><input id="capture_signIn_locale_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="locale"><input id="capture_signIn_recaptcha_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_d34u9f7n5rfbbxff15mylzwnf0kk0ptlycjvzrur" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2008290?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><bko-ixknmbakvuss></bko-ixknmbakvuss><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>